TW206155B - - Google Patents

Description

20615^ Α6 Β6 經 濟 部 + 央 標 準 局 貝 工 消 费 合 作 社 印 五、發明説明（) 専利申請茱第81103008號 ROC Patent Appln. H〇81103008 修片之屮Ak明yig>-5頁-附件㈢ AierjpdLPages 3-5 |>f the Chinese Ijoec ioftt Banflf Enel. 1 (民U月士丨曰修正並送呈> 本發明主要係两於新穎之泥煤-衍生之生物活性産物 ,及製造此産物之方法-本發明亦關於含有?此等産物之 B藥及美容组成物，及製備含有該泥煤-衍生之生物活 性産物之B藥及/或美容®方之方法^ 以多種方法，使用不同萃取介質，及使用此種含有泥 煤-衍生之生物活性成分提取物製備化妝品及翳藥:方面 目的之産品係習知的。 ； 此等已知方法掲示於波蘭專利公報第1 2 4 1 1 Q號（彳b學 I * · · ' 摘要101⑽，78854e);依據此習知方法，泥煤-衍生之 生物活性産物之裂備，可葙著使空氣乾燥之粗泥煤原料 進行一级及二级龄水解，接箸使因而所得之水解物酸化 ,並以随後之第二次鹺化作用而分離不溶固暖部份，酸 化此度清掖相，並以酵及醚萃取方式除去殘瘡物質；在 該方/法中，由有機萃取作用所得之水溶液相為掖態之泥 煤-衍生之生物活性産物。 由上述波蘭専利公報所得之已知液態產物為於离濃縮、接近鉋 和的氮化納水溶掖中之泥煤一衍生之活性成份的溶液*其當長時 間貯存時並不穩定•此外•其含有與此組成物之生物活性相闢之 大過量中性無機物質，由於產物韻積大’故難W處理•貯存及加 工。 本發明之主要目的係提供一種不具上述缺點之產物*即安定、 易於調配成»_及獸翳產物且可Μ固態或任何庙宜溶液調配成美 容製劑之產物。 (請先閱讀背面之注意事項再填寫本頁) 裝. .訂· ’綠’ 本紙張尺度適用中國國家標準(CNS)甲4規格(210X297公釐)20615 ^ Α6 Β6 Ministry of Economic Affairs + Central Standards Bureau Beigong Consumer Cooperative Printed V. Description of Invention () Application No. 81103008 ROC Patent Appln. H〇81103008 Revised Film Akmingyig >-5 pages-Annex AierjpdLPages 3 -5 | > f the Chinese Ijoec ioftt Banflf Enel. 1 (民 U 月 士 丨 日 應 訂 備) > The present invention is mainly two novel peat-derived biologically active products, and the method of making this product- The present invention also relates to a B-medicine and cosmetic composition containing these products, and a method for preparing the B-medicine and / or cosmetic® method containing the peat-derived biologically active product. ^ In various ways, using different extraction media, And the use of such extracts containing peat-derived biologically active ingredients for the preparation of cosmetics and pancakes: the products for this purpose are known.; These known methods are shown in Polish Patent Gazette No. 1 2 4 1 1 Q (彳 b 学 I * · · Abstract 101⑽, 78854e); According to this known method, the cracking of peat-derived biologically active products can be used to carry out primary and secondary ageing of crude peat raw materials that are air-dried Hydrolysis The resulting hydrolysate is acidified, and the insoluble solid and warm parts are separated by the second subsequent oxidation, acidified to clean the phase, and the residual material is removed by fermentation and ether extraction; in this method / method The aqueous solution phase obtained by organic extraction is a peat-derived biologically active product in the state of Ye. The known liquid product obtained from the above Polish Gazette is the mud in the solution of sodium nitrate dissolved in concentrated, nearly planed water. The solution of coal-derived active ingredients * is not stable when stored for a long period of time. In addition, it contains a large excess of neutral inorganic substances that are separated from the biological activity of this composition. It is difficult to handle because of the large product rhythm. • Storage and processing. The main purpose of the present invention is to provide a product that does not have the above-mentioned disadvantages * that is stable, easy to formulate into »_ and animal products, and can be formulated into a cosmetic preparation in a solid state or any Miaoyi solution. (Please first Read the precautions on the back and then fill out this page) Packing ... Order · 'Green' This paper scale is applicable to China National Standard (CNS) Grade 4 (210X297mm)

Λ6 B6 五、發明説明（2 ) 特別地•有關泥煤-衍生之生物活性產物在睡藥目的（即製造賂 销组成物）方面之用途•目前對於提供一插很適用此目的之固態 形式有強烈’之霈求。先前苜試目檫係港縮泥煤-衍生之生物活性 物質之已知水溶液，並使其脫鹽•但無法得到正面結果，此係由 於话性成份吸箸於结晶固睦相内之故*如此導致话性減低•因此 非常難Μ找出使此液體组成物鞞變成粉末狀之適宜方法。 令人意外的鱼：若在獠缩之前液餛組成物先〇勤.： 倍，亦卽以水使纽成物鹾積稀釋鞟倍V則發現可得到.正· ·* . * 面之结杲〇 一 钱此，本s明提供一種具有上述度鲇待m之方法，岢 由含有泥煤-衍生之生物活性成份之高谤缩無機鹽.（待. 別.是氡化钔）溶液，以脱磺水（如蒸®水）.稀釋該溶液 ，接著以逆彦析.濃缩.及澄清作·用广而士:得泥煤-衍·生. 之生物活性産物》因此所得之溶液葙箸殺菌作用及噴菝 ； .： 卜: 乾燥而易於轉換成殺菌之固證産物，非常適於欲逹成之 目的。稀釋較佳以歆倍於欲稀釋·之蒺缩液..之量的水進行 . * ,較佳為5至8倍。 用於加工波Μ專利公·報第1 2 4 1 1 Q號所得産物之本g .明 方法是由下列步铤構成：自後萃取水相中排除殘留有.機 溶劑，在威壓下通·過燒结之陶磁材料過猫.使不溶部份分 餻’，以數倍睦積之蒸搵水稀釋g透液，並以逆毖析進行 脱盈化，以分陡過量之堀物鹽，主要為氛化納，作為谚 本紙張又度適用中國國家標準（CNS)甲4規格（2:10 X 297公發） ---------------(-------裝------訂----線 (請1閱-:»'!«'而之注念麥項再塡寫本頁) 經濟部中央標準局員工消費合作社印製 經濟部中央楳準局貝工消費合作社印製 五、發明説明（） 析液，接箸摄缩此脱鹽化溶液，以離心澄清.化，並以通 過薄膜過，濾器.（如Mill ipore® 過嫌器）過.跋殺菌，.所 得微生物學上乾淨之溶液可視情況嗔霧乾燥；殺菌後之產物（掖 饅或固體）可調配成美容、或»翳稱組成物。視情況而定， 此濃縮及灌清溶液可不經殺薗及嗔隳乾燥•而以任何適宜稀釋液 •於數種美容組成物中使用作為成分。 較佳在噴锈乾燥步驟中，入口溫度設定至约18«TC , 同時出口溫度設定至9 0 eC。 本發明方法與波蘭専利公報第124110號之方法難於前文中一道 敘述，其用途並不侷限於此項組合，而_用於由含有泥煤一衍生 之生物活性成份之無機鹽（特別是氣化1納）之高濃编水溶液•得到 坭煤一衍生之生物活性產物之方法。 本發明方法與波蘭專利公報第124110號之方法一道敘 述费，其用途並不侷限於此項组合，而適用於由含有泥 煤-衍生之生物活性成份之無機鹽（待別是氛化納）之 高嬝结水溶液，得到泥煤-衍生之生物活性産物之方法 〇 由本發明方法所提供之泥煤-衍生之生物活性産物含 有不高於70%重’，較好是不高於6Q%重之無機盏，特別 是氮化納。由於最適産物其氛化納嬝度儘可能低較佳， 特別是對需要較高濃度之B第用途及美容用途，如對面 部保養而言，較低之氛化納瀑度，如55 %甚至更低為最 佳，尤其是以稀釋或逆接析步驟製得時為然。 此方法以摄缩及涅清化步想终止時，產物為潘缩（或 "濃稠”）溶液，在本説明軎中代表之"濃縮泥煤萃取物" \ 為具有1 . G 2至1 . 0 9 g / π 1密度，且乾燥固體含量不低於5 » 5 - 本紙張尺度遑用中國國家楳準(CNS)肀4規格(2】〇Χ297公*) (請先閲讀背面之注意事項再填寫本頁) Λ 6 B6 20615b 五、發明説明（4 ) (請先閲讀背而之注意事項#塡寫本頁) 重之暗棕色液體。在乾燥固體中，氛離子含量以氛化鈉 計，係不高於70%,較佳不高於60%，且13：水溶液之pH 值為5.0至6. 5,通常約6.0;在某些情況下，例如該濃 縮泥煤萃取物之某些美容用途的情況下，不另外實施殺 菌步驟並不一定有害。 另一方面，當産物意欲用於製備醫藥組成物時，殺菌 步驟將為必要性者，特別是在若非必要性之情況下，最 好使用噴霧乾燥之進一步步驟，此種噴霧乾燥步驟後所 得之産物係呈粉末狀，且特別適用於某些B藥組成物之 製備。此種型態之最佳産物為以” T 0 L P A R Τ ο Γ f製劑”設 計之市售産品，T0LPAR^Torf有限公司，ul. Mydlana 2 , Wroc law,波蘭之登記商標；縮寫TTP將於本説明書 中代表該産物。 經濟部中央橾準局员工消费合作社印製 本發明亦關於含有上述泥煤-衍生έ生物活性産物作 為活性成份之醫藥組成物，待別是含有以乾固體計，不 超過70%重，較佳不超過60 %重之無機鹽（特別是氣化 m )之産物，及《藥可接受性載劑之醫藥組成物。含於 此種醫藥组成物中之泥煤-衍生之生物活性産物較佳為 上述定義之TTP。此翳藥製劑含有泥煤-衍生之生物活性 産物及醫藥可接受性載_材料，較佳重量比例為約1: 5 至1 : 2 5之間，且最好介於1 ·· 9及1 : 1 9之間。 本發明又關於一種製備含有泥煤-衍生之生物活性産 物且呈凝膠狀之轚藥配方的方法，此方法之待擞為殺菌 -6 - 81. 10,000張（Π) 本紙張尺度逍用中《國家楳準(CNS)甲4規格(210x297公;¢) 061515Λ6 B6 V. Description of the invention (2) In particular • Regarding the use of peat-derived biologically active products for the purpose of sleeping pills (ie the manufacture of bribery compositions) • Currently there are solid forms that are suitable for this purpose Strongly begging. The previous alfalfa trial Sassafras was a known aqueous solution of Hong Kong shrinkage peat-derived biologically active substances, and desalinated it. This leads to a reduction in speaking performance. Therefore, it is very difficult to find a suitable method for turning this liquid composition into a powder. Surprising fish: If the liquid wonton composition is used before shrinking: times, and the water is used to dilute the new product and the product is diluted, then it is found to be available. Positive · * * * The knot of the face As a result, this article clearly provides a method with the above-mentioned degree of catfish treatment m, which consists of a high-condensation inorganic salt containing peat-derived biologically active ingredients. (To be. Don't. Is radonized thorium) solution, Dilute the solution with desulfurized water (such as steamed® water). Then dilute the solution, concentrate it, and clarify it. Use it widely: get the bioactive products of peat-derived and raw. So the resulting solution The sterilization effect and smilax sibiricum; .. BU: It is dry and easy to be converted into a sterilized solid product, which is very suitable for the purpose of success. The dilution is preferably carried out with an amount of water that is twice as large as the shrinkage liquid to be diluted. *, Preferably 5 to 8 times. This product is used to process the product obtained by the patent publication No. 1 2 4 1 1 Q. The method is composed of the following steps: the residual organic solvent is removed from the aqueous phase after extraction, and the solvent is passed under the pressure. · The sintered ceramic material has passed the cat. Make the insoluble part separate, dilute the permeate with the distilled water of several times and accumulate it, and deinterfere with reverse decantation to divide the steep excess of Hori salt , Mainly for chlorination, as a proverb paper, it is also applicable to the Chinese National Standard (CNS) A 4 specifications (2:10 X 297 public) --------------- (- ----- installed ------ ordered ---- line (please read 1-: »'!«' And remember Mai Xiang then write this page) Printed by Employee Consumer Cooperative of Central Bureau of Standards, Ministry of Economic Affairs Printed by the Beigong Consumer Cooperative of the Central Bureau of Industry and Commerce, Ministry of Economic Affairs 5. Description of the invention () The liquid is separated, and the desalted solution is shrunk to clarify by centrifugation, and pass through the membrane and filter. (Such as Mill ipore ® Pass the sterilizer). After sterilization, the resulting microbiologically clean solution may be dried by fogging as the case may be; the sterilized product (steamed bread or solids) can be formulated into a beauty, or a singular composition. Depending on the situation , This concentration and irrigation The solution can be dried without chrysanthemum and dehydration. Instead, use any suitable diluent. It can be used as an ingredient in several cosmetic compositions. Preferably in the rust drying step, the inlet temperature is set to about 18 «TC, and the outlet temperature is set Up to 90 eC. The method of the present invention is difficult to describe together with the method of Polish Gazette No. 124110, and its use is not limited to this combination, but for inorganic salts derived from biologically active ingredients derived from peat (Especially 1 ng of gasification) high-concentration braided aqueous solution • A method for obtaining a biologically active product derived from Ni coal. The method of the present invention and the method of Polish Patent Gazette No. 124110 are described together, and their use is not limited to this item Combination, which is suitable for the method of obtaining peat-derived biologically active products from a high-condensation aqueous solution containing inorganic salts of peat-derived biologically active ingredients (to be distinguished from chlorinated sodium). Provided by the method of the present invention Peat-derived biologically active products contain not more than 70% by weight, preferably not more than 6% by weight of inorganic lamps, especially sodium nitrate. Due to the most suitable product, its nitrification degree It may be better if it is low, especially for B-side applications and cosmetic applications that require higher concentrations, such as for facial care, lower saturating nano-degrees, such as 55% or lower, are best, especially for dilution Or it can be obtained by reverse reverse analysis step. This method is based on the shrinking and niching step, the product is a pan (or "thick") solution, and the "concentrated peat" represented in this description. The extract " \ has a density of 1. G 2 to 1.0 9 g / π 1 and a dry solids content of not less than 5 »5-This paper scale uses the Chinese National Standards (CNS) 4 specifications (2 】 〇Χ297 公 *) (Please read the precautions on the back before filling out this page) Λ 6 B6 20615b V. Description of the invention (4) (Please read the precautions ## 塡 write this page) Heavy dark brown liquid . In dry solids, the content of atmospheric ions is not more than 70%, preferably not more than 60% in terms of sodium hydride, and 13: the pH value of the aqueous solution is 5.0 to 6.5, usually about 6.0; in some In some cases, such as in the case of some cosmetic uses of the concentrated peat extract, it is not necessarily harmful if the sterilization step is not carried out separately. On the other hand, when the product is intended to be used in the preparation of a pharmaceutical composition, the sterilization step will be necessary, especially if not necessary, it is better to use a further step of spray drying, which is obtained after such spray drying step The product is in powder form, and is particularly suitable for the preparation of certain B-drug compositions. The best product of this type is a commercial product designed with "T 0 LPAR Τ ο Γ f preparation", a registered trademark of T0LPAR ^ Torf Co., Ltd., ul. Mydlana 2, Wroc law, Poland; the abbreviation TTP will be published in this The product is represented in the instructions. The present invention is also printed by the Consumer Cooperative of the Central Ministry of Economic Affairs of the Ministry of Economic Affairs. The present invention also relates to a pharmaceutical composition containing the above-mentioned peat-derived biologically active product as an active ingredient. The product of inorganic salts (especially gasification m) not exceeding 60% by weight, and the pharmaceutical composition of "pharmaceutically acceptable carrier." The peat-derived biologically active product contained in this pharmaceutical composition is preferably TTP as defined above. This paniculum preparation contains peat-derived biologically active products and pharmaceutically acceptable carrier materials. The preferred weight ratio is between about 1: 5 and 1: 25, and preferably between 1. 9 and 1. : Between 1 and 9. The present invention also relates to a method for preparing a gel-like formula containing peat-derived biologically active products. The method is to be sterilized-6-81. 10,000 sheets (Π) The paper is used in the scale `` National Standards (CNS) A 4 specifications (210x297 g; ¢) 061515

A6 B6 經濟部中央標準局員工消費合作社印製 五、發明説明（5) 之藥用植物萃取液逐新與粉化之泥煤-衍生之生物活性 産物之殺菌溶液合併，所得混合物藉著添加膠質氣化矽 而膠凝，且所.得之凝膠以脂肪成份，如優卡因（e u c e r i n e ) 及礦脂之預殺菌混合物搗碎，較佳液體成分對氣化矽之 重量比例為3 0 : 2 Q ,且凝膠對脂肪组合物之重量tb例為 32: 68至34: 66。本文中，較佳亦使用TTP作為粉化或 濃缩之泥煤-衍生之生物活性産物。 可包括藥用植物萃取物及其他可用於美容用途之辅助 及濃缩成份，芳香组成物及載劑材料之美容製劑，含有 0.01至10 %重之本發明泥煤-衍生之生物活性産物，較’ 好為0_05至1.00 %重，且最好為0.05至0.10%重。 載劑材料可為醇類之小溶液，所有型態之乳液，凝瞟 ，.泡沬组成物及脂肪載劑；選自上述物質之一特定載劑 之用途可調配成本發明各種型態之美容裂'劑，如毎天身 體保養用之補強劑，乳膏，香脂，清潔乳等，及洗髮精 ，髮麗香，泡沫浴组成物，所有均可添加泥煤-衍生之 生物活性産物。 由原始粗泥煤材料（如治療性泥煤）所產生之泥煤_衍 生之生物活性産物（簡稱為泥煤萃取物）含有礦物與有 機化合物之良好平衡量，如下列元素之無機鹽：硼，矽 ，鐵，鎂，錳，飼，錫，鎳，鈣/銀，及鈉•·有機化合 物，如呈游離態及鹽之胺基酸：；聚糖，在水解作用下部 份降解/反應成脱氣糖及/或胺基糖者；泥煤，特別是 "·請先閲"背面之注意#項再場寫本頁) -丨裝· .11. 一琛· 本紙張尺度適用中國國家標準（CNS)甲4規格（210 X 297公釐） ^06151>A6 B6 Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy V. Description of the invention (5) The medicinal plant extracts are merged with the powdered peat-derived bioactive product sterilization solution, and the resulting mixture is added with colloid The gasified silicon gels, and the resulting gel is crushed with a pre-sterilized mixture of fat ingredients, such as eucerine and petrolatum. The weight ratio of the preferred liquid ingredient to the gasified silicon is 30: 2 Q, and the weight tb of the gel to fat composition is 32: 68 to 34: 66. Here, TTP is also preferably used as a pulverized or concentrated peat-derived bioactive product. May include medicinal plant extracts and other auxiliary and concentrated ingredients that can be used for cosmetic purposes, aromatic compositions and carrier material cosmetic preparations, containing 0.01 to 10% by weight of the peat-derived biologically active product of the present invention. 'Good is 0_05 to 1.00% by weight, and preferably 0.05 to 0.10% by weight. The carrier material can be a small solution of alcohol, all types of emulsion, gel, foam composition and fat carrier; the use of one of the above substances can be formulated into a specific carrier for the use of various types of beauty 'Cracker' agents, such as reinforcing agents for daily body care, creams, balsams, cleansing milk, etc., as well as shampoo, scent, foam bath compositions, all can be added with peat-derived bioactive products. Peat-derived biologically active products (referred to as peat extracts) produced from raw coarse peat materials (such as therapeutic peat) contain well-balanced amounts of minerals and organic compounds, such as inorganic salts of the following elements: boron , Silicon, Iron, Magnesium, Manganese, Feed, Tin, Nickel, Calcium / Silver, and Sodium • Organic compounds, such as amino acids in free state and salt :; Polysaccharides, partially degraded / reacted under the action of hydrolysis Degassed sugars and / or amino sugars; peat, especially " · please read " at the back of the note "#Item and then write this page)-丨 装 · .11. Yichen · This paper size is for China National Standard (CNS) Grade A 4 (210 X 297 mm) ^ 06151 >

A6 B6 經濟部中央標準局員工消费合作社印製 五、發明説明（6) 冶療性泥煤係已知，且經確認之生物梢物及微生物源材料 ;由於其具有營養及剌激成份，因此對人類及哺乳動物 極有益，·因此，泥煤-衍生之生物活性组成物含有對於 活有機體為比例待性之上述物質，此可用以解釋含有泥 煤-衍生之活性産物及組成物之美容及醫ά製劑所具之 有益效果、恃別是當藥用植物萃取物亦存在於配方中時 ，更可觀察到新美容組成物之良好效果。適宜藥用植物 萃取物之選擇傜依此種萃取物於美容上之已知南造而異 ，改良製劑的活性能使美容製劑之成分與使用値居的需 要舆需求相配合β 本發明έ下列寅例作進.一步的待戡化與閫述。 g m 1 ： 最初以1000 iu之空氣乾燥之粗泥煤材料，依波蘭專利 第124110號之已知步驟，得到約1〇升最之於飽和氯化納水溶 液之泥煤-衍生之生物活忭成分浓液•在減颳下通'過燒 結之陶磁過濾器過濾該溶液，K便在脫鹽化作用之前將溶 液澄清•如此所得之澄清溶液含有佔乾塊約95%之氯化納， 此乾塊揹成該溶液之約32% M.道量訃，此澄淸溶液之體稍約為7 升。 此澄清溶液以5至8倍置之蒸皤水稀釋，且稀釋液使 用DDS裝置利用逆毖析技術進行脫鹽化步驟，脱鹽化作 用進行3至4小時，使主要為参化納之過置無機鹽以谚透 液之型式分雔，脱鹽化之組成物含有約65-70%之固體 本紙張尺度適用中國國家標準（CNS)甲4规格（210 X 297公梦） ---------------f-------裝------1T-----^ ^ (請先閱冶背面之注*?#項再塡寫本頁) 0615οA6 B6 Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy V. Description of the invention (6) Known and confirmed biotech materials and microbial source materials for the smelting peat system; as they have nutritional and stimulating ingredients, Very beneficial to humans and mammals. Therefore, the peat-derived biologically active composition contains the above substances that are proportional to living organisms. This can be used to explain the beauty and beauty of peat-derived active products and compositions The beneficial effects of medical cosmetic preparations are distinguished when the medicinal plant extracts are also present in the formula, and the good effects of the new cosmetic composition can be observed. The choice of suitable medicinal plant extracts varies according to the known cosmetics of such extracts in cosmetics. The activity of the improved preparations can match the ingredients of the cosmetic preparations with the needs of the people who use them. Yin example makes progress. One-step waiting to be carried out and described. gm 1: coarse peat material initially dried with 1000 iu of air, according to the known procedure of Polish Patent No. 124110, about 10 liters of peat-derived biological activity component most saturated with sodium chloride aqueous solution is obtained Concentrate • The solution is filtered through a sintered ceramic filter under reduced scraping, K will clarify the solution before desalination • The clear solution thus obtained contains about 95% sodium chloride in the dry block, this dry block Back to about 32% M. of the solution, the body of this clear solution is about 7 liters. This clear solution is diluted with distilled water 5 to 8 times, and the diluted solution is subjected to a desalination step using a reverse decantation technique using a DDS device, and the desalination is carried out for 3 to 4 hours, so that it is mainly placed over Inorganic salts are divided into liquids in the form of proverbial liquids, and the desalinated composition contains about 65-70% solids. This paper scale is applicable to China National Standards (CNS) Grade 4 (210 X 297 Gongmeng) ----- ---------- f ------- install ------ 1T ----- ^ ^ (please read the note on the back *? #item and then write this page ) 0615ο

Α6 Β6 經濟部中央標準局員工消費合作社印製Α6 Β6 Printed by the Employees Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs

五、發明説明（7 ) 氛化鈉，因而所得之6-7升體積之溶液於Buechi旋轉蒸 發器中濃编4-5次，而捎得約20%乾塊之濃縮溶液， 所得悉却i容液使用B i 〇 f u g a -丨丨e r a e 11 s離心裝贸（流龉分 離器）沿消化，接箸Μ通過M i 1丨i f>〇re 1R >過濾器過濾殺 菌0 所得之微生物學上為純的溶液，以出口溫度設定在90 Ί0且入口溫 度設定在180 °C之無水乾燥器中噴菝乾燥，乾燥粉末之 産量约2Q0ge 審例2 : 簧例1所得産物用以製備亦含有對某些疾病有協同改 良治療效桌之藥用植物萃取物其凝膠及软莆醫藥组成物 ，例如以下列方式製備抗小腿靜脈瘤潰焖之凝膠及軟資 .:.使用20g之hippocastanaceous (馬栗屬）之萃取物， l〇g金盞草萃取物，6Qg甘油，J /1 g上k實Μ 1所得之粉 末狀ΤΤΡ, 0.1 g水楊酸，1.0 g蒸餾水及8.8 g Aerosil (膠質二氧化矽），Μ獲得凝膠態製劑。 液體（非揮登性）成份在使用前，以在回流下加熱2 小時之方式殺菌，藥用植物萃取物與甘油及ΤΤΡ水溶液 组合，並舆甘露醇混合，且在連續搜拌下逐漸添加氣化 矽至所得混合物中。 相同的，為了獲·得軟資组成物，使角下列成份：2 0 g hippocastanaceous (馬栗.屬）·之萃取物，lQg金盞草萃 取物，O.lg水揚酸，O.lg之實例1所得呈粉末狀之TTP (請"間-"而之注念箨項再塡寫本頁) 裝- 、11. 線- 本紙張尺度適用中困國家標準（CNS)甲4規格（210 X 29^公釐） ^06155 Λ 6 Π 6 經濟部中央標準，而貝工消费合作社印製 五、發明説明（8 ) 及2.Qg AerosilR (膠質氣化矽）β 至於脂肪成份，係使用22g優卡因（eucerine)及45.8g 礦脂之物質之混合物；藥用植物萃取物在回流下加熱約 2小時而殺菌，優卡因及礦脂亦同樣殺菌，液體成分小 心地與氣化矽混合以得凝膠，其依次以殺菌並冷卻至室 溫之脂肪成份搗碎，而得到當貯存不會分離之安定軟膏 〇 上逑所得之凝膠及軟音同時用於小腿靜脈瘤潰爛之治 療，潰爛處以凝膠製劑治療，同時周圍未患病皮虜以軟 音治療，膠質氣化矽之添加據信可促進除濕乾燥，同時 藥用植物及泥煤-衍生之分據相信為製劑之治療效果， 脂肪成分則可保持瘌及皮虜之彈性，所得结果與以標準 方法治療之對照組病患比較，而接受此新式治療之病患 僳選自己患有疾病數目（有時數年）而未有顯著正面治 療效果之病患，以本發明组成物治療之病患在最先數週 内，比對照组病患顯現更佳之結果。 奮例卩： 使用S例1所製得之産物，以裂備呈錠劑或可置於膠 囊内顆粒狀之翳藥配方， 呈粉狀之殺菌泥煤-衍生之生物活性組成物以1: 9之 重量比例與載劑溏合，至於載劑，可使用乳糖與潤滑物 質以44: 1之重量比例之裩合物，即MYVATEXRTL (伊士 曼-柯逹之商榡名），50網目粒徑之乳糖與MYVATEXRTL -1 0 - (請先閲讀背而之注意事項再填寫本頁) 裝- 訂- 線. 本紙Λ尺度逍用中國國家樣毕(CHS)T4規格(210x297公货) 81. 4. 10,000張（H) 經濟部屮央標準局员工消赀合作社印製 £0615b Λ6 五、發明説明（9 ) 细粒地分解，以使約70%之塊狀物可通過100網目之篩 子，活性组成物與載薄I之所得混合物之部份調配成含有 5 mg活性成分之錠劑，各錠劑之總重為50mg;活性組成 物與載劑之相同混合物之其他部份使用適置之乙酵（40 體積％ )顆粒化，若需要，使顆粒過篩並研磨，接著使 用TTP,與載劑以19·· 1之比例混合而请充成各膠囊含有 5 mg活性成分量之膠囊。 測試上述所得之錠劑，使用Erweka裝置，在37°C+/-2 °C下於人工胃液中測量其崩解時間；人工胃液之製備 如下：2.Qg氛化納及3.2g胃液素溶於7 Bl鹽酸中，且添 加蒸皤水至lOQflml之體積，所得溶液之pH值約為1.2， 具有5. In·直徑及0.0498 g结重之錠劑之崩解時間為6分 鐘。 關於本發明之數種美容製劑之進一步實例，為具不同 型式组成物及設計成不同用途，並含有衍生自泥煤之生 物活性成份之有利添加，其中敘逑如滋補剤，香脂，乳 音，乳液，洗髮精，泡沫浴組成物之製劑。 奮例4 : 配有攪拌器之反應容器中餓入150g之以1: 1乙酵冰溶 液萃取甘菊花所得之甘菊萃取液，及lg上述之TTP,將 50g甘油加至所得混合物中，攪拌3種物質以得均勻混合 物，随後，將預先調配好之第二種混合物導入相同容器 中，第二種混合物包括340g 95: 5乙醇：水溶液，lg水 -1 1 - (請先閲讀背而之注意事項再填寫本頁) 裝· 訂_ 線· 本紙張尺度边用中B »家楳毕(CNS)甲4規格(210x297公¢) 81. 4. 10,000張（1[) 206155 Λ 6 Η 6 經濟部中央橾準局貝工消赀合作社印製 五、發明説明（10) 楊酸及0.5 g甘露醇；以攪拌混合此兩種混合物以形成均 勻溶液，接著添加3g香料组成物TILIANA H4308， T I L I A N A Η 4 3 0 8 為波蘭 W a r s a w 之 F a b r y k a S y n t e t y k 〇 w Zapachowgch Pollena-Aroaa (合成香料工作室 Pollena -Aroma)之産品；接著溶液藉添加454.5 g蒸皤水調至 lOOQnl结體積，趙鑛攙拌直至獲得均質混合物。 在上述步驟中，使用波蘭藥物管理局所要求之86%甘 油，甲酵及水及波蘭工業標準BN-75/6193-01之95%濃 度之乙醇。 所用之濃缩泥煤萃取物為具l.Q20-1.090g/ml密度及 不低於5%乾固體含量之暗棕色液體；1%水溶液之PH值 為5.0-6.5,甘菊萃取物為具有0.9160至0 . 9 5 0 3 g/ml密 度及52-56體積％乙醇含量之紅棕色液體。 上述所得之補強製_適用於所有種類之皮虜，其為澄 澝溶液而無任何固體，其顔色為黃色，PH值為4. 28且乙 醇含量為4 5 . 9 2體積5：,以水揚酸含量計算之總酸度不低 於0.1重董％, —般為0.23重量％，貯存12個月後之製 劑不會喪失上述任何特性。 奮例R : 重覆上述實例4所逑之步驟，而不同處僅為以金盞花 宰取物及 FINUS Η4625 (亦為 Fabryka Syntetykow Zapachowych Pollena-AToma之産品）組成物，取代甘 菊萃取物及TILIANA H4308香料組成物，且使用相同莫 -1 2 - (請先閲讀背而之注意事項再填寫本頁) 裝· 訂， 線· 本紙張尺度遑用t β «家«毕(CHS) T4規格(210x297公釐） 81. 4. 10,000張（II) Λ 6 B65. Description of the invention (7) Sodium oxychloride, so the resulting 6-7 liter volume of the solution is concentrated 4-5 times in a Buechi rotary evaporator, and a concentrated solution of about 20% dry block is obtained. The liquid was digested along with B i 〇fuga-丨 丨 erae 11 s centrifugal packing (fluid separator), then the filter was sterilized by M i 1 丨 i f > 〇re 1R > filter. Microbiology The above is a pure solution, dried in a dry dryer with an outlet temperature set at 90 Ί0 and an inlet temperature set at 180 ° C. The yield of dried powder is about 2Q0ge. Case 2: The product obtained in Example 1 is used to prepare For some diseases, the medicinal plant extract with synergistic and improved therapeutic effect table, its gel and soft medicine composition, for example, the preparation of anti-calf venous aneurysm gel and soft capital in the following way: use 20g of hippocastanaceous (Marsh chestnut) extract, 10g calendula extract, 6Qg glycerin, J / 1g powdered TTP, 0.1g salicylic acid, 1.0g distilled water and 8.8g Aerosil ( Colloidal silica), M to obtain a gel formulation. Liquid (non-volatile) ingredients are sterilized by heating under reflux for 2 hours before use. Medicinal plant extracts are combined with glycerin and TTP aqueous solution, mixed with mannitol, and gradually added with continuous search and mixing. Silicone into the resulting mixture. In the same way, in order to obtain and obtain the soft-funded composition, the following ingredients are used: 20 g hippocastanaceous (Horse chestnut.) Extract, lQg calendula extract, O.lg salicylic acid, O.lg The TTP in powder form obtained in Example 1 (please "quote between") and write a page on this page. 装-， 11. Thread-This paper scale is applicable to the National Standards for Sleepy (CNS) A 4 specifications ( 210 X 29 ^ mm) ^ 06155 Λ 6 Π 6 Central Standard of the Ministry of Economic Affairs, and printed by the Beigong Consumer Cooperative Society V. Description of Invention (8) and 2.Qg AerosilR (Colloidal Vaporized Silicon) β As for the fat component, it is used A mixture of 22g eucarine and 45.8g petrolatum; medicinal plant extracts are heated under reflux for about 2 hours to sterilize. Eucarine and petrolatum are also sterilized. Mix to obtain a gel, which is sequentially crushed with fat ingredients that are sterilized and cooled to room temperature, and a stable ointment that will not separate when stored is obtained. The gel and soft sound obtained from the above are used for the treatment of calf venous ulcer , The ulcers were treated with gel preparations, and the surrounding unaffected skin was treated with soft sounds, The addition of quality gasified silicon is believed to promote dehumidification and drying. At the same time, the medicinal plants and peat-derived fractions are believed to be the therapeutic effect of the preparation. The fat component can maintain the elasticity of the skin and skin, and the results obtained are in accordance with standard methods. Compared with the control group of patients who were treated, the patients who received this new treatment selected the number of patients who had the disease (sometimes several years) but did not have a significant positive therapeutic effect. The patients treated with the composition of the present invention were Within the first few weeks, the patients showed better results than the control group. Endeavour: Use the product prepared in Example 1 in a split form to prepare tablets or tablets that can be placed in capsules. The powdered sterilized peat-derived bioactive composition is 1: The weight ratio of 9 is combined with the carrier. As for the carrier, a compound of lactose and a lubricating substance in a weight ratio of 44: 1, that is, MYVATEXRTL (Eastman-Ke's commercial name), 50 mesh particle size can be used Lactose and MYVATEXRTL -1 0-(please read the precautions before filling in this page) Binding-Order-Line. This paper Λ scale is used in China National Sample (CHS) T4 specifications (210x297 public goods) 81.4 . 10,000 sheets (H) Printed by the Employee Consumer Cooperative of the Bureau of Standards, Ministry of Economic Affairs £ 0615b Λ6 V. Description of the invention (9) Finely decomposed so that about 70% of the lump can pass through a 100-mesh sieve, active Part of the resulting mixture of the composition and carrier I is formulated into a lozenge containing 5 mg of active ingredient, the total weight of each lozenge is 50 mg; other parts of the same mixture of active composition and carrier use a suitable B Leaven (40% by volume) granulated, if necessary, sieve and grind the granules, then use TTP, and carrier 19 ·· mixing ratio of 1 to request charging each capsule contains 5 mg of active ingredient amounts of capsules. To test the lozenges obtained above, using the Erweka device, the disintegration time was measured in an artificial gastric fluid at 37 ° C +/- 2 ° C; the preparation of the artificial gastric fluid was as follows: 2. Qg chlorinated sodium and 3.2g gastrin were dissolved 7 Bl hydrochloric acid, and add distilled water to the volume of 10Qflml, the pH of the resulting solution is about 1.2, the disintegration time of the tablets with 5. In · diameter and 0.0498 g set weight is 6 minutes. Further examples of several cosmetic preparations of the present invention are those with different types of compositions and designed for different uses, and containing beneficial additions of biologically active ingredients derived from peat, such as tonic, balsam, milky, Preparation of lotion, shampoo, foam bath composition. Example 4: In a reaction vessel equipped with a stirrer, 150g of chamomile extract obtained by extracting chamomile flowers with 1: 1 ethyl yeast ice solution and lg of the above TTP were added 50g of glycerol to the resulting mixture and stirred 3 kinds of substances to get a homogeneous mixture, then, the second mixture prepared in advance is introduced into the same container, the second mixture includes 340g 95: 5 ethanol: aqueous solution, lg water-1 1-(please read the back first Please pay attention to this page and then fill out this page) Binding · Order _ Line · This paper is used in the standard B B »Homewood Bi (CNS) A 4 specifications (210x297 cm) 81. 4. 10,000 sheets (1 [) 206155 Λ 6 Η 6 Printed by the Ministry of Economic Affairs, Central Bureau of Industry and Fisheries Cooperative Society V. Description of the invention (10) Salicylic acid and 0.5 g of mannitol; the two mixtures are mixed by stirring to form a homogeneous solution, and then 3 g of the perfume composition TILIANA H4308 is added, TILIANA Η 4 3 0 8 is a product of Fabryka S yntetyk ○ w Zapachowgch Pollena-Aroaa (Synthetic Perfume Studio Pollena -Aroma) of Warsaw, Poland; then the solution is adjusted to a volume of 100Qnl by adding 454.5 g of steamed water, Zhao Mine Mix until homogeneous Compounds. In the above steps, 86% glycerin, formazan and water as required by the Polish Drug Administration, and 95% ethanol in the Polish industry standard BN-75 / 6193-01 are used. The concentrated peat extract used is a dark brown liquid with a density of 1.20-1.090g / ml and a dry solids content of not less than 5%; the PH value of 1% aqueous solution is 5.0-6.5, and the extract of A red-brown liquid with a density of 0.9160 to 0.9 5 0 3 g / ml and an ethanol content of 52-56% by volume. The supplementary force obtained above is applicable to all types of skins, it is a clear solution without any solid, its color is yellow, PH value is 4.28 and ethanol content is 45.9 2 volume 5 :, with water The total acidity calculated from the content of salicylic acid is not less than 0.1% by weight, generally 0.23% by weight. The formulation after 12 months of storage will not lose any of the above characteristics. Endeavour R: Repeat the steps described in Example 4 above, except that the calendula extract and FINUS Η4625 (also a product of Fabryka Syntetykow Zapachowych Pollena-AToma) are substituted for camomile extract and TILIANA H4308 Fragrance composition, and use the same Mo-1 2-(Please read the precautions before filling this page) Binding · Order, Thread · This paper is not used t β «家« 毕 (CHS) T4 specification (210x297 Mm) 81. 4. 10,000 sheets (II) Λ 6 B6

£〇61bS 五、發明説明（ll) (請先閲讀背而之注意事項稃填寫本頁) 耳及钃積比例。所得補強製_適用於乾燥及脆弱皮虜， 同樣的此製劑為澄清液而無任何固體顆粒，PH值為4. 30 ,總乙醇含量為45.82醴積％，且绝酸度為0.27重量％ ,當貯存12値月後，舆實例4所得之製劑相同，此製劑 並未有任何改變β 啻例： 重覆實例4之步费[,但選擇鼠尾草葉之萃取物代替甘 菊萃取液，且選擇香料LELIA 90368(Pollena-Ar〇Ba, Warsaw)取代TILIANA H4308,鼠尾草葉之萃取物俗以 5 0 *C 乙醇萃取乾燥之乾燥鼠尾草葉而獲得，且其具有 棕色，鼠尾草臭味及0 . 9 1 6 Q至0 . 9 5 0 3之密度，其含有5 2 至56%之乙酵；所得之臉部保養劑待別適用於油性皮虜 此製劑為具有暗黃色之澄清均質液體；PH值，乙醇含 量及酸度可與實例4之保養劑之諸值相比擬。 窨例7 : 下列组成物證明對避免或治療periodontosis (齒周 膜病）為特別有效之凝膠： 經濟部中央標準局员工消费合作社印製 24 . 0g 甘菊萃取液 3.0g 鼠尾草葉萃取液 〇 · 3g 水揚酸 〇 . 2g 甘露酵£ 〇61bS V. Description of the invention (ll) (Please read the back-end notes first and fill in this page) Ear and stubble ratio. The resulting supplement is suitable for dry and fragile skins. The same preparation is a clear liquid without any solid particles. The PH value is 4.30, the total ethanol content is 45.82%, and the acidity is 0.27% by weight. After 12 months of storage, the preparation obtained in Example 4 is the same, and there is no change in this preparation. Β Example: Repeat the step fee of Example 4 [, but choose the extract of sage leaves instead of chamomile extract, and choose The spice LELIA 90368 (Pollena-Ar〇Ba, Warsaw) replaces TILIANA H4308, the extract of sage leaves is obtained by extracting the dried sage leaves with 50 * C ethanol, and it has brown, sage smell and 0. 9 1 6 Q to 0.9 5 0 3 density, which contains 5 2 to 56% of the yeast; the resulting facial care agent is not suitable for oily skin. This preparation is a clear homogeneous liquid with a dark yellow color ; PH value, ethanol content and acidity can be compared with the values of the maintenance agent of Example 4. Example 7: The following composition proves to be a particularly effective gel for avoiding or treating periodontosis (peridontal membrane disease): Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 24.0g Camomile Extract 3.0g Sage Leaf Extract 〇 · 3g salicylic acid 〇. 2g mannan

0 . 1 g TT P 至lQQ.Qg之市售凝謬基劑 -1 3 - 81. 4. 10,000張（II) 本紙ft尺度遑用中《國家«毕（CNS)甲4規格（210x297公 經濟部屮央櫺準局员工消费合作社印製 2061^^ Λ6 ___Π6_ 五、發明説明（12) 窨例8 : 將下列小心稱重之成分導入配有機械攪拌器之20Q0ml 體積之反應容器中： 270 g之以50 %乙醇萃取甘菊花之甘菊萃取物，此萃取 物為紅榇色液體，具有0.9160-0.9503 g/ml密度，且乙 醇含董約55體積％， 50 g之86 3：甘油，依據波蘭藥品管理局之要求； 30g之以70%乙醇萃取肥皂草根所得之肥皂草萃取物 ，此萃取物為紅棕色液體，密度為0 . 9 6 3 0 - 0 . 9 8 1 0 g / m 1 ，且乙醇含量約75體積％ ; l.〇g之本濃縮泥煤萃取物，為具1.02-1.D9 g/Bl密度 之暗棕色液體，以氣化納計不超過2 3：之氣離子；乾固體 含量不低於5 %,萃取物之1%水溶液之pH值為6.0。 充分混合上列成分，並於其中添加預先製備之含lg水 揚酸之260g 95%乙醇溶液，於混合溶液中，添加383g 蒸皤水及5g香料组成物TILIANA H34Q8,並攪拌直至播 得均勻溶液，分析製劑並貯存於2QQ ml體積之零星瓶中 ，所得裂_適宜作為毛髮保養製劑，其為澄清淡乳白液 體，含有約4 5體積％之乙醇，pH值為4. 5,以水楊酸計 之總酸度不低於0.1重量％ ;此製劑適用於金色頭髮， 製劑在貯存12锢片期間仍維持其持性而未有改變。 官例9 ： 依實例8所述之步驟，但使用相同順序及比例之馬尾 -1 4 - (請先閲讀背而之注意事項再填寫本頁) 裝< 訂· 線- 本紙Λ尺度遑用中β S家楳毕(CHS) T4規格（210x297公《：) 81. 4. 10,000張（Π) ^06155 Λ 6 η 6 經濟部中央捸準局貝工消费合作社印製 五、發明説明（13) 草植物萃取物及香料組成物FINUS Η4625,以取代甘菊 萃取物及TILIANA H430 8組成物。馬尾草植物萃取物為 具0.9160-0.9503 g/ffll密度及55體積％乙醇含置之緣棕 色液體。 所得製劑適用於所有種類之頭髮，其為澄清透明之液 體而無任何固體部份，且為黃棕色，在貯存12値月後， 其PH值，乙醇含量，總酸度及安定性均與實例6所述之 製劑相同。 奮，例1 0 : 重覆實例8所述之步驟，僅不同處為使用相同順序及 比例之強烈奪麻葉萃取物及香料组成物LELIA 90368 (Fabryka Syntetykow Zapachowych Pol. l'ena-Arona 之 産品），取代甘菊萃取物及TILIANA H43Q8組成物e所 用之藥用植物萃取物為橄攬綠色，且具有0.9160至 0.95Q3g/Bl密度及約55體積％之乙醇含量，製劑適用於 所有種類之頭髮。 啻例1 1 : 通常美容乳液為以化學及機械方式作用於皮虜上之脂 肪物質之分散液，事實上，由於施用方便且流鱷與皮虜 間之作用較佳，因此較適宜使用液體，特別是乳液乳蕾 ,其可輕易地滲透至皮虜深層，因此可預防皮虜因年齡 之改變，美容乳液主要僳用於清潔乾燥及脆弱皮虜，據 此，其需不含有侵蝕性之揮發油脂，同時通常含有類似 -1 5 - (請先閲讀背而之注意事項冉填寫本頁) 裝- 訂- 線· 本紙張尺度遑用中國國家榣毕(CNS)T4規格(210X297公:Jt) 81. 4. 10,000張（ίΐ) Λ 6 Π 6 £061^5 五、發明説明（14) (請先閲讀背而之注意事項再填寫本頁) 甘菊萃取物或小麥胚芽萃取物之適宜藥用植物萃取物； 此種美容乳液中添加泥煤-衍生之生物活性産物可進一 步增進其正面效果，特別是此新配方為下列者： TT P 0 . 0 5 g 蘆薈萃取物 2 0 . 0 0 g 甘油 3 . 0 0 g eucerine 2 . 0 0 g 白石蠟油 1 . OOg 三乙胺 1 . 0 〇g AerosilR (膠質氣化矽） 4 . 0 0 g 窨例1 2 : 經濟部中央標準局员工消费合作社印製 當於標準營養及再生乳音配方中，使用Τ Τ Ρ及小心選 擇之脂肪載劑時，觀察改良之再生結果，ΤΤΡ之使用量 為0.01-1.0 0重量％，藥用植物窣取物（視乳蕾所欲處 理皮虜之種類加以選擇）之量至少為0. (35-1.0Q重量％ ，抗菌製劑之量為0.0 5-1.00重量％，協同香料組成物 之量為0.01-0.05重量％ ,及構成整個組成物之97.00-99 · 50重量％之呈水乳液狀之脂肪載劑。此脂肪組成物 需對活性成份為良好載劑，且可被皮慮接受者β較好此 為 35-45611〇61^116，8-14確脂，2.5-4撤攬油，6-10甘油 及35-40水（所有量均為重量％ )之乳液，較好藥用植 物萃取物為金盞花萃取物，甘菊萃取物，百里香萃取物 等，較佳之配方如下： -1 6 - 本紙张尺度边用中國醸家樣毕（CNS)f 4規格（210X297公放) 81. 4. 10,000張（H)0.1 g TT P to lQQ.Qg commercial coagulation base-1 3-81. 4. 10,000 sheets (II) of the paper ft scale used in the "National« Bi (CNS) A 4 specifications (210x297 public economy Printed 2061 ^^ Λ6 ___ Π6_ by the Ministry of Industry and Consumer Affairs of the Ministry of Industry and Commerce. V. Description of the invention (12) Example 8: Introduce the following carefully weighed ingredients into a 20Q0ml volume reaction vessel equipped with a mechanical stirrer: 270 g The chamomile extract of chamomile flowers extracted with 50% ethanol, this extract is a red color liquid, with a density of 0.9160-0.9503 g / ml, and ethanol contains about 55% by volume, 50 g of 86 3: glycerin, based on Requirements of the Polish Medicines Agency; 30g of Soapwort extract obtained by extracting Soapwort roots with 70% ethanol. This extract is a reddish brown liquid with a density of 0.96 3 0-0.98 1 0 g / m 1 , And the ethanol content is about 75% by volume; 1.0 g of this concentrated peat extract is a dark brown liquid with a density of 1.02-1.D9 g / Bl, and the gas ion does not exceed 23: 3 ; The dry solid content is not less than 5%, and the pH value of the 1% aqueous solution of the extract is 6.0. The above ingredients are thoroughly mixed and added in advance. 260g 95% ethanol solution containing lg salicylic acid, add 383g distilled water and 5g perfume composition TILIANA H34Q8 to the mixed solution, and stir until a homogeneous solution is broadcast, analyze the preparation and store in a 2QQ ml volume sporadic bottle , The resulting crack _ suitable as a hair care preparation, which is a clear light milky liquid, containing about 45 volume% ethanol, a pH of 4.5, the total acidity in terms of salicylic acid is not less than 0.1% by weight; this preparation It is suitable for blonde hair, and the preparation maintains its retention without changing during the storage of 12 tablets. Official Example 9: Follow the steps described in Example 8, but use the same order and ratio of horsetail-1 4-(Please read first (Notes to be filled out and then fill out this page) Binding < Order · Thread-This paper is used in the beta β S family tree (CHS) T4 specifications (210x297) ": 81. 4. 10,000 sheets (Π) ^ 06155 Λ 6 η 6 Printed by the Peking Consumer Cooperative of the Central Equatorial Bureau of the Ministry of Economic Affairs 5. Description of the invention (13) Grass plant extract and fragrance composition FINUS Η 4625, to replace chamomile extract and TILIANA H430 8 composition. Horsetail plant The extract has a density of 0.9160-0.9503 g / ffll and 55% by volume Alcohol contained brown liquid. The resulting preparation is suitable for all types of hair, it is a clear liquid without any solid part, and is yellow-brown, after storage for 12 months, its PH value, ethanol content, total The acidity and stability are the same as the formulation described in Example 6. Fen, Example 10: Repeat the steps described in Example 8, except that the same order and ratio of the strong leaves extract and fragrance composition LELIA 90368 (Fabryka Syntetykow Zapachowych Pol. L'ena-Arona product) are used. , The medicinal plant extract used in place of chamomile extract and TILIANA H43Q8 composition e is olive green, and has a density of 0.9160 to 0.95Q3g / Bl and an ethanol content of about 55% by volume. The preparation is suitable for all types of hair. Example 1 1: Generally, cosmetic lotions are dispersions of fatty substances that chemically and mechanically act on skins. In fact, liquids are more suitable for use because of the ease of application and the better interaction between crocodiles and skins. In particular, emulsion milk buds can easily penetrate deep into the skin, so it can prevent the skin from changing due to age. The beauty lotion is mainly used to clean dry and fragile skin. According to this, it must not contain aggressive volatilization. Grease, usually also contains -1 5-(please read the precautions and fill in this page first) Binding-Order-Thread · This paper is not based on China National Standards (CNS) T4 (210X297): Jt 81. 4. 10,000 pieces (ίΐ) Λ 6 Π 6 £ 061 ^ 5 5. Description of the invention (14) (please read the precautions before filling in this page) Suitable medicines of chamomile extract or wheat germ extract Use plant extracts; the addition of peat-derived bioactive products to this cosmetic lotion can further enhance its positive effects, especially the new formula is the following: TT P 0. 0 5 g Aloe extract 2 0. 0 0 g glycerin 3. 0 0 g eucerine 2. 0 0 g white Paraffin oil 1. OOg Triethylamine 1.0 〇g AerosilR (Colloidal Vaporized Silicon) 4.0 0 g 窨 Example 12: Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs as a standard nutrition and regenerated milk sound formula When using ΤΡ and carefully selected fat carrier, observe the improved regeneration results, the amount of TTP used is 0.01-1.0 0% by weight, medicinal plant extracts (depending on the type of skin bud to be treated The amount of selection is at least 0. (35-1.0Q wt%, the amount of antibacterial preparation is 0.05-1.00wt%, the amount of synergistic fragrance composition is 0.01-0.05wt%, and 97.00-99 constituting the entire composition · 50% by weight of a fat carrier in the form of an aqueous emulsion. This fat composition needs to be a good carrier for the active ingredient, and can be considered by the recipient β is preferably 35-45611〇61 ^ 116, 8-14 Fat, 2.5-4 withdraw oil, 6-10 glycerin and 35-40 water (all amounts are% by weight), the preferred medicinal plant extracts are calendula extract, chamomile extract, thyme extract The preferred formula is as follows: -1 6-This paper uses the Chinese standard (CNS) f 4 specifications 210X297 public place) 81. 4. 10,000 (H)

20615B Λ 6 Η 6 經濟部屮央標準局貝工消费合作社印製 五、發明説明（15) Eucerine 3 9 . 0 0重量份 碾脂 1 1 . 5 Q重量份 橄欖油 3 · 1 3重量份 甘油 7 . 80重量份 水 3 8 . 0 0重量份 NIPAGINA A (抗睹製劑） 0 . 4 0重量份 T T P 0 . 05重量份 金盞花萃取物 0 . 1 0重量份 合成香料 0 . 0 2重量份 共 1 0 0 . 0 0重量份 Eucerine 4 2 . 0 0重量份 礦脂 8 . 50重董份 橄攬油 3 . 0 8重量份 甘油 7 . 9 0重量份 水 38 . 0 0重量份 NIPAGINA A (抗菌製劑） 0 . 40重量份 TTP 〇 . 05重置份 甘菊萃取物 0 . 0 2重量份 合成香料 〇 . 0 5重量份 -17- (請先閲讀背而之注意事項#填寫本頁) 裝· 訂· 線- 共 ΐϋϋ. 〇G重量份 本紙張尺度边用中a B家標準（CHS) T4規格(210X297公¢) 81. 4.〗0,000張（Π) ^061515 Λ 6 It 6 五、發明説明（16) 經濟部屮央標準局貝工消费合作社印製 弯例1 2 : 刮鬍後使用之製劑含有0.01-1重 萃取物，卜30重量之藥用植物萃取 油，水楊酸及甘露醇於水-醇溶液， 取物為甘菊，金盞花，百里香，蘆 之藥用植物萃取液，由於甘油可影 亦為有益者，其可加速製劑於面部 深層，因此可增強活性泥煤組成物 有益效果。 較佳之配方如下： TTP 甘菊萃取物 甘油 水揚酸 甘露醇 乙醇（濃度9 5 % ) 香料组成物 蒸餾水 加至 窗例1 4 : 依據下列配方製備洗髮精組合物 漂布之藥用植榭萃取物 15 強烈之奪麻葉萃取物' 20 GAMAL SBS-11(清潔劑） 30 量％之T T P作為泥煤 物，1-8重量％之甘 較佳之藥用植物萃 薈萃取物及類似有益 雄皮膚之彈性，因此 之塗佈及滲透至皮虜 及藥用植物萃取物之 0 . 1 0重量份 1 5 . 0 0重量份 5 . 0G重量份 〇 . 10重量份 〇 . 1 Q重量份 1 0 . 0 0重量份 〇 · 30重量份 1 0 0 · 0 0重置份 • 0 0 g 7 . 5 0重量 ％ .0 0 g 10.00重量 ％ .0 0 g 15.00重量 ％ (請先閲讀背而之注意事項再填寫本頁) -18- 本紙》尺度边用中《 B家榣毕(CNS) T4規格（2丨0X297公*) 81. 4. 10,000¾ (|〇 經濟部屮央標準局员工消费合作社印製 06lb〇 五、發明説明（17) GAMAL NO- 3 (清潔劑） Aseptina 乙醇 B R 0 N 0 P 0 L (防腐劑） 氯化銷 水 於92重置份之上述洗髮 TTP,以獲得100重量份之 萃取物可用以取代強烈之 奮俐1 5 : 製備下列洗髮精组成物 馬粟萃取物 金盞花萃取物 GAHAL SBS- 1 1 GAMAL N0-3 Aseptina 乙醇 BR0N0P0 L 氣化納 水 Λ 6 Η 6 2 0 .00 g 10 .0 0重 量 % 0 .40 g 0 • 2 0重 量 % 1 • 60 g 0 .8 0重 置 % 0 • 04 g 0 .0 2重 量 % 6 _ 0 0 g 3 .0 0重 量 % 10 6 • 96 g 5 3 .48重 量 % 共 2 0 0 • 00 g 10 0, 0 0重 量 % 精組 成物 中， 添 加8 重量 份 之 本發明洗髮精，其他藥用植物 奪麻葉萃取物。 1 3 · 0 0 g 2 2 . 0 0 g 3 0 . 0 0 g 2 0 . 0 0 g 0 . 4 0 g 1 . 6 0 g 0 . 0 4 g 6 . 0 0 g 1 0 6 . 9 6 g 共 2 0 0 . 0 0 g -1 9 - 本紙張尺度边用中國》家楳準（CNS) Ή規格（210X297公货) 81. 4.丨0,000張（Π) (請先閲讀背而之注意事項洱填寫本頁) Λ 6 H6 20615b 五、發明説明（18) (請先閲讀背而之注意事項再填寫本頁) 於95重量份上述组成物中，添加5重量份之ΤΤΡ,以 得10 0重量份之本發明洗髮精。 啻例1 fi : 牙膏含有〇·(Π-ί).1{)重量％ 2TTP作為濃縮泥煤萃取物 ,1-10重量％之精油或其組成物或其他水果香油，5-10 重量％之甘油，0.10-10重量％之藥用植物萃取物，及 20-35重量％之分散於45-60重量％水中之清潔物質，及 1-2重董％之染料及白化成分。 二 氣 化 鈦 可 使 用 作 為 白 化 成 分 ΤΤ Ρ本身 亦可作為抗 添 加 剤 鼠 尾 草 葉 9 甘 菊 或 金 盞 花 萃取物可作為有益 較 佳 藥 用 植 物 萃 取 物 〇 較 佳 之 配 方 如 下 沉 澱 之 碩 酸 鈣 15 0 .00g m 酸 m 60 .00g 甘 油 7 0 .0 0 g 藥 用 植 物 萃 取 物 5 .0 0 g TT P 0 .50g 二 氧 化 鈦 10 .0 Og 精 油 ( 或 薄 荷 > 檸 樣 等 香 油 ) 5 .0 Og 水 4 0 0 .0 0 g 染 料 - 少 量 例 11 ； 浴 邇 製 劑 ： 在 用 以 獲 得 本 發 明 泥 煤 -衍生 之生物活性 經濟部中央標準局员工消费合作社印製 -20- 81. 4. 10,000張（1[) 本紙張尺度遑用中Β國家榣準（CNS)肀4規格（210x297公;it) 06ιδΰ Λ 6 Η6 五、發明説明（19) 産物之方法中，待別是當将液態轉化成粉末態時，此為 ,，塞 中馥阻 物 _ 些 産，某 副鹽有 該鈣含 在為亦 ，鹽物 爨機産 步無質 化之鹽 鹽離等 脱分此 之他； 物其 産 ， 副銷 成化 雔氛 分為 納成氣 化構為 氣%要 將95主 鹽 酸 硫 及 物 化 有 之TT 中為 構物 結合 晶化 結機 之有 馥等 機此 無 ， 等物 此合 於化 機 成 子胺 分， 低糖 之聚 生有 衍中 - 其 煤泥.： 當檫 ，之 在鹽 存浴 之對 中可 物其 産於 副由 質傜 鹽 ， 於者 份益 成有 等係 此時 ，鹽 等浴 酸為 烯作 富 用 -使 酸鹽 基此 質 性 蘭理 波物 於及 物學 産化 副其 此試 ，测 此中 據院 ，究 故研 之 C 果gl 效10 I. ο 夕 e 額In 加Ba 添之 性an 活zn 準P0 使質：^!组 可性下P5油 其要如TT精 現需方之或 發不配塞油 而之佳阻精例 ，鹽較含松奮 此 現 發 未 院 究。 研途 此用 於容 由美 ，為 浴作 容可 美其 為此 作因 用 ， 鹽 物 成 含物 資取 香萃 髮物 頭植 穎用 新藥 之 Q/ 童 2 重逹 ο 1X , I 1分 .0成 ο電 P 靜 TT抗 之之 % % 量量 3 3 (請先閲讀背而之注意事項#填寫本頁) 裝< 訂- 線. 經濟部+央標準局KX工消费合作社印製 分 成 之 燥 乾 度 過 虜 皮 及 髮5 領-0 防05 預ο 0 之，% %油量 量甘重 劑 定 安 及 剤 腐 防 之 % 量 E 3 之 % 量 重 至 水 及 r亦 肪於 脂至 物 ·’ 動液 由溶 有類 含酵 蕾之 香鹽 本銨 ，化 份氯 成及 電胺 靜甲 抗三 於之 至得 所 胺 之 生 安 為 作 可 本紙張尺度逍用中明國家楳準(CNS)甲4規格(210x297公¢) 81. 4_ 10,000張（|!) £66153 Λ 6 Β6 經濟部屮央標準局貝工消费合作社印51 五、發明説明（20) 定 劑 之 增 稠 劑 為 美 容 性 醇 至 於 預 防 頭 髮 及 皮 儀 過 度 乾 燥 之 試 劑 為 植 物 油 9 其 同 時 可 作 為 共 乳 化 劑 9 及 易 於 塗 佈 及 读 透 香 膏 ( 恃 別 是 其 活 性 成 份 TT 'P 及 藥 用 植 物 萃 取 物 ) 之 甘 油 而 由 於 酸 性 環 境 可 使 細 m 之 複 製 停 止 > 因 此 本 發 明 之 香 膏 含 有 0 · 0 1 重 量 % 之 檸 樣 酸 或 富 馬 酸 及 已 知 為 BRO N 丨0P 0L及 香 料 組 成 物 之 防 腐 劑 〇 較 佳 配 方 如 下 * 二 甲 胺 及 氛 化 銨 鹽 之 醇 類 溶 液 3- 4 重 量 % 美 容 性 醇 3- 4 重 量 % T1 'P 0 . 0 1 -1 0 重 量 % 稠 化 之 藥 用 植 物 萃 取 物 0 . 0 1 -1 0 重 量 % 甘 油 1 . 5 重 量 % 植 物 油 達 2 . 0 重 量 % 檸 檬 酸 或 富 馬 酸 0 . 1 重 量 % BR0N0P 0L 0 . 1 重 量 % 香 料 组 成 物 0 . 3 重 量 % 蒸 餾 水 至 10 0 重 量 % 例 19 美 容 面 膜 為 已 知 具 有 許 多 不 同 百 的 之 美 容 製 劑 而 治 療 性 泥 對 皮 虜 及 身 體 亦 已 知 具 有 有 益 效 果 9 據 信 由 泥 煤 之 製 備 生 物 活 性 之 泥 煤 -衍生之組成物之方法所得之後 萃 取 泥 煤 亦 可 用 於 美 容 用 途 t 後 萃 取 泥 煤 含 有 在 齡 水 解 方 法 中 所 不 具 有 之 活 性 體 溶 液 » 由 於 在 中 和 後 泥 煤 之 極 -22- (請先閲讀背而之注意事項#填寫本頁) 本紙張尺度逍用中國國家樣毕(CNS)T4規格(210X297公货) 81. 4. 10,000» (H) Λ 6 Η6 ^06155 五、發明説明 高吸附性質，因此證明為美容面膜之有價值成分，為了 壹富具有多種有價值成份之後萃取泥煤，則添加存在於 中性泥煤中之中性治療性泥及腐殖酸，且於獲得泥煤衍 生之生物活性組成物之方法中，自齡性水解物中分離， 此種组成物於上述Balneologic研究院中測試並發現可 適用於美容用途。 較佳配方如下： 後萃取泥煤 1Q0 . Og 中性治療性泥或泥煤 20.Og 腐殖酸皤份 10 . Og 碩酸鎂 10 . Og 氣化鋅 5 . 0 g .檸檬酸等 0 . lg 蕖用植物萃取物或粉狀植物材料 5.0g 蒸皤水 適當 下列論點及解釋傜蘭於本發明産物之生物觀點，即關 於生物活性特擞及此等産物之相容性，待別是與其使用 作為醫藥品之相容性，下列縮寫將使用如下： TTP TOLPA®5 Torf 製劑（波蘭，ul. Mydlana 2'， Wroclaw之Torf有限公司之商樣） IFN産生於受细酴侵犯之細胞的蛋白質，為到處存在之 胞嘧啶（組纗荷爾蒙），IFN基因存在於所有細胞 中，IFN主要以蛋白質或糖蛋白質引發，剌激製造 -2 3 - 本紙張尺度遑用中國國家標毕(CHS) Τ4規格(210x297公址) (請先閲讀背而之注意事項再填寫本頁) 裝< 訂- 線· 經濟部中央標準扃Μ工消费合作社印製 81. 4. 10,000張（Ιί) Λ 6 Π 6 五、發明説明（22) IFN之IFN基因之物質稱為引發劑，IFN引發之方法 為高度讁節且複雜之生化方法；控制IFN製造之負 及正諝節子基因已經確認，少量之IFN可以自發産 生而無需任何可偵測之引發劑，此種IFN類有時稱 為”生理上之I F N類"。 IF N以三種主要分子形式存在於天然界中： I FN- α (或白血球IFN)， IFN-彡（絲蛋白IFN)，及 IFN- y (免疫 IFN)。 IFN-α 及 IFN-/S 為 Ι-IFN 類型，IFN-y 為 II - IFN 型。 IFH類之主要生物活性為抗病毒，antiproliferative ( 抗腫瘤）及免疫活性。 各種型態之IFN傜以天然及重組製劑以商業性製得， 且可使用作為治療腫瘍，病毒及數種其他疾病之藥物。 CTL=細胞毒性T之淋巴細胞 NK細胞=天然殺手細胞 IL-1, IL-2為已知可剌瀲T細胞及其他淋巴細胞（包含 B細胞）之延長生命作用之内白血球 (interleukins) 經濟部中央標準局貝工消费合作社印製 (請先閲讀背而之注意事項再填寫本頁) RPMI 1640用以生長人類及其他白血球之组織培養介質 (B u f f a 1 〇 之 R 〇 s w e 1 1 P a r k M e π 〇 r i a 1 I n s t i t u t e 之 缩寫）； FCS =胎牛血淸（用於白血球分析，由於其可含有模擬 -2 4 - 本紙張尺度边用中國國家《毕（CHS)甲4規格(210x297公龙） 81. 4.丨0,000張（H) Λ 6 Η6 五、發明説明（23) 内白血球作用之發育物質，因此需預先測試）； EMCV =腦脊讁病毒，對人類非病因之老鼠PiC0rna病毒 ，其通常於IFN生物分析中作為試驗性病毒； A-549人類腺癌細胞糸一由於其對IFN-α,冷，及y之 高敏感性因此可用於IFN之生物分析，此細胞条被 推薦可用於IFN標準化中之WHO鑑定； Μ T T 3 -〔 4，5 -二甲基瞜唑-2 -基〕-2，5 -二苯基四唑啉 溴化物，係數種生物分析中，以ELISA掃描器測定 被殺滅細胞或細胞生長之試劑（Hansen等人，J. I ηu η ο 1. M e t h. 1 9 8 9 , 1 1 9 , 2 0 3 - 2 1 0 ); L929老鼠细胞条，一般用於分析老鼠IFN及人類或老鼠 TN P ; TO腫瘍壞死因子，牛細胞，（相當小之蛋白質，對蛋 白水準酵素非常敏感），係由單細胞及巨细胞所製 得（TNF-ct亦已知為於人類及動物中引起惡質病之 惡病質因子）； 經濟部屮央標準局E3：工消费合作社印製 (請先閲讀背而之注意事項#填寫本頁) 以LPS(脂聚糖），病毒，及許多其他試劑剌激後 所産生者，對許多病毒感染及新生細胞為非常毒性 ,亦可作為絲蛋白之生長因子，與發炎性反應連接 ，相關型態TNF-β (淋巴細胞）主要傜由T細胞及 某些其他細胞所産生； PBL末稍血液白血球，由健康血液捐贈者所得之正常人 類白血球，是由"巴比層"（在红細胞及血漿間之界 -2 5 - 本紙»尺度逍用中《明家«準(CNS) Ή規格（210X297公釐) 81. 4_ 】0,000張（H) 經濟部中央標準局貝工消费合作社印製 Λ 6 Π 6 五、發明説明（24) 面相）分離得。各別捐賄者之PBL對各種胞漿引發 劑之反應僳依損贈者之遣傳而定。高反應者及無反 應者經過確認，得知其係與PBL對ΤΤΡ之反應有關。 使用弱引發劑比使用強引發劑，如病毒時，還更能見 到値體對於IFN或TNF誘發劑反應的差異，此像由於對弱 引發劑之反應為”全部或沒有"型，然而，病毒幾乎經常 引發可偵測數量之胞漿。 引發劑之耐受性：亦稱之為次反應性狀態。傜發生於引 發劑之單一劑量之投藥後，例如，PBL暴露於引發劑（ 如病毒）20小時後；細胞停止進一步製造IFN 。次反應 性狀態經常持缠約7天。可能為完全或部份。此反應性 使強力引發劑之治療應用形成困難及/或無效。弱IFN 引發劑亦不引發次反應性狀態或其耐受性係小的。 許多天然藥物傜由具有免病性質之藥用植物中萃取得 β ΤΤΡ為其中之一 β ΤΤΡ改變許多在活體内及活體外不同 之免疫功能。其起動均衡之免疫作用，以非特定能力使 所有受動器路徑（CD4助劑，弱CD8抑制劑，CTL, {JK細 胞，及活性巨抗菌素）活化，而對於正常细胞不具有毒 性。 TTP在一般創傷之治療上具有恢復健康的效應。TTP之 低劑量可撤弱的刺·激IL·1及IL - 2之生産。高劑量可抑 制牛細胞的合成。 與TTP之相對試驗傜依下列之方法進行： -26- 本紙張尺度边用中明國家樣準（CNS)Τ4規格(210X297公釐） 81. 4.〗0,000張（Η) (請先閲讀背而之注意事項#填窝本頁) 裝· 線- ^06155 Λ 6 Η 6 經濟部中央樣準爲貞工消费合作社印31 五、發明説明（25) 得自健康血液損贈者之PBL以氣化銨處理純化。培養 介質為 RPMI 1640 加 1096FCS。在 37°C、5% C02 下培養 約8X106細胞/ ml, 20小時。受菌細胞且白質之抗濾 過性病毒活性.在人類A549細胞内偽以細胞病理效應抑制 分析》亦使用MTT方法測量被殺死之細胞。 活性係在L929細胞内測量。為了定出IFN型，單獨的 IFN樣品傜以不同之抗IFN血清處理lh。抗濾過性病毒活 性傜與未處理之製劑比較。 此試驗顯示TTP刺激内生干擾素（IFNs)以及腫瘤壊死 因素（TNF)之産生β此反應為劑量相關的。 ΤΤΡ之7種經分析之市售品具有可比較之生物活性， 如免疫剌瀲劑及牛細胞引發劑。 -曾經發現：各別血液損贈者之白血球對ΤΤΡ之反應有 很多變異。各種劑量之PBL經發現像無反醱的。此可反 應遣傳上的背景。 使用效力強大之多源抗血清，如抗- IFN-a(Cantell) ，抗-IFN-α Ly (Namalwa)(得自 Κ· Fantes),及抗-IFN-y (Cantell)以中和以TTP處理20h在表面之PBL之抗 濾過性病毒活性。 中和分析之结果經發現與各別血液損贈者之指印相類 似。換言之。由皆體産生之IFN型比率有很大變異，PBL 之分離成黏着與未黏箸部份可增強誘發之胞漿合成。 以NDV對IFN誘道之次反應性（耐受性），在以TTP起 -2 7 - (請先閲讀背而之注意事項再填寫本頁) 裝- 訂' 線. 本紙張尺度边用中B Η家樣準（CNS) T4規格(210X297公*) 81.欠 10,000張（Π) Λ 6 It 6 經濟部屮央樣準局貝工消赀合作社印製 五、發明説明（26) 始剌激PBL後20小時發現為極小或没有的。 在人體内之PBL之全部7組試驗，如IFN及INF引發劑 ，經發現傜對引發IFN及/或INF具活性的。用於IFN引 發最佳之TTP濃度為30-100// g/ml,且用於TNF引發為 100-20G# g/nil。2Q0# g/ml之劑量對PBL係次毒性的， 但TNF合成較INF還快，且較中度細胞毒性之發生快。 前述之結論為在TTP製藥中之活性主體之實驗傜得自 含有機，初级結合糖，胺基酸，糖醛酸，腐植酸物質及 含微元素礦物鹽之泥煤之萃取物之免疫活性部份。動物 中之 LDso 像 >2400 mg/kg per os〇 未發現TTP具有致突變性、對生殖細胞具毒性、對胚 胎具毒性，産生畸形或致癌性之活性。ΤΤΡ顯示沒有引 起過敏病的性質，且没有局部刺激的活性。 治療適用於包含慢性病及重複之呼吸条統發炎。 附表1-24係藺於各種的生化學，例如毒性、血液的， 及免疫的試驗。此等表顯示並提供有關ΤΤΡ之親和及生 物活性之生物有關訊息。 值得注意的是在藥劑内之活性成份之濃度，如申諳專 利範圍第13項所示，可以比保養成分（如申請專利範圍 第1 4項所示）高，傜基於下列理由： 藥劑偽依單位配_藥製備，其中活性成分之含量偽在嚴 格的控制下，例如，在橥片中、濃度傜依含有效每日劑 量（或一部分）活性成分之藥片大小而定。 -2 8 - (請先閲讀背而之注意事項#填寫本頁) 裝. 訂- 線- 本紙張尺度逍用中《國家樣毕(CNS) Τ4規格(210X297公龙:） 81. 4. 10,000張（|[) Λ 6 Η 6 五、發明説明（27) 活性成分之有效成分，例如ΤΤΡ ，在充滿於腠囊中之 顆粒内，較好僅5 wt %,以達成足夠之藥片大小，並且 使膠囊機適於施用。 另一理由係大部份藥劑為口服投藥，且活性成份分佈 於整體内。即使其以非常低之濃度到達皮虜細胞，治療 之影饗傜值得注意的。 再者，保養組成物-不同於藥劑-傷以相當不可控之量 使用，區域性的塗佈，以不同的速率滲透於不同的細胞 中。 . 某些组成物，如洗髮精，幾乎立即洗掉，與頭髮或身 體之接觭時間短，且相對的含有更多有效的成分；其他 的係每日塗佈許多次，因此應具有低的有效成分。 最後，如牙蕾的情形，係與嘴裡的黏液成分相接觴， 活性成分之滲透傺比經過皮虜更容易，且活性成分之濃 度可以更低。 (請先閲讀背而之注意事項再填寫本頁) 經濟部屮央楳準局员工消费合作社印製 -29- 81. 4. 10,000張（|[) 本紙張尺度逍用中·》家樣準(CNS) Ή規格(210x297公;!!：) λ 6 η 6 五Λ發明説明（28) 經濟部屮央梂準局Α工消奸合作社印51 O r-H Cs3 « 〇 o c〇 C〇 o c-—。 Csj «~H in o o O C3 C=> C3 a o O CD m 齡 httf b〇 o o C3 O O €3 C3 C3 Q G CD C3 +1+1 +1+1 +1+1 +1+1 +1+1 +1+1 c〇 ς〇 o寸 ITD t>* CO C5 CM Cs. 卜CO ιο m Η 1 ιο lO ΙΟ UD iro itd t- o to <x> CD CD O C3 C3 C=J CP O cd cr> O CD 艏 級 cn ¢0 ^ CS3寸 CO cn CO -LJ m 寸CO 寸ΙΛ ΙΟ CO 00 〇 t—t CO 州 躲 CO CD i-H CO Cs3 cot-H <N CQ co •Ν 娜b〇 s—/ +1+1 +1+1 +1+1 +1+1 +1+1 +1+1 m CD o o co CO CD 〇〇co in co xn csi 00 t— ◦ 〇 c〇L〇 卜卜 co <xS o〇 t>- 翎 eo co tn in 卜CO in in rh CO O CD r-» 〇〇 CD CQ CJ CO ψ ·4 i 1 —CO y^-i to寸 〇 CO CO CNJ CD — 职 m CD C3 CD O CP o CD O C=> CD CD <=> 鏟Ο +1+1 +1+1 +1+1 +1+1 +1+1 +1+1 05 CQ <〇 co ^ o? cn 00 ^ to寸 CD ◦ C3 — oo 00 c〇 OO OO CD «r-4 O CD C? C3 CD 1—i O — 暖 Q -. * CL· C=> l>- CD卜 o卜 ◦卜 Q卜 O卜 e-H 泰 CL, .b〇 a CD CP <=> CP o 6"» _ • - • m e-η C'J IT3 CD CJ to « b〇 昶 m ix< m —30— (請先閲讀背而之注意事項再填寫本頁) 裝. 線- 本紙張尺度逍用中國Η家楳毕(CNS)>P4規格（210父297公龙） 8L 4. ]0,000張(H) 五、發明説明（29) 雄 m Λ 6 Π 6 經濟部屮央標準局ΕΧ工消伢合作社印Μ20615B Λ 6 Η 6 Printed by the Beigong Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (15) Eucerine 3 9 0 0 parts by weight of crushed fat 1 1.5 Q parts by weight of olive oil 3 · 1 3 parts by weight of glycerin 7. 80 parts by weight of water 3 8.0 parts by weight of NIPAGINA A (anti-glare preparation) 0.40 parts by weight of TTP 0.05 parts by weight of calendula extract 0.1 0 parts by weight of synthetic perfume 0.0 2 parts by weight of total 1 0 0 .0 parts by weight Eucerine 4 2 .0 parts by weight petrolatum 8.50 parts by weight olive oil 3.08 parts by weight glycerin 7.9 parts by weight water 38.0 parts by weight NIPAGINA A ( Antibacterial preparation) 0.40 parts by weight TTP 0.05 replacement parts chamomile extract 0.02 parts by weight synthetic fragrance 0.05 parts by weight -17- (please read the back to the precautions # fill in this page) Binding · Ordering · Line-Total ϑϋ. 〇G parts by weight of the paper used in the standard a B home standard (CHS) T4 specification (210X297 public ¢) 81. 4.〗 0,000 sheets (Π) ^ 061515 Λ 6 It 6 5 2. Description of the invention (16) Printed example 1 by the Beigong Consumer Cooperative of the Bureau of Standards, Ministry of Economic Affairs: The preparation used after shaving contains 0.01-1 heavy extract Bu 30 weight medicinal plant extract oil, salicylic acid and mannitol in water-alcohol solution, the extract is medicinal plant extract of chamomile, calendula, thyme, reed, because glycerol can also be beneficial, its It can accelerate the preparation in the deep layer of the face, so it can enhance the beneficial effects of the active peat composition. The preferred formula is as follows: TTP chamomile extract glycerol salicylic acid mannitol ethanol (concentration 95%) perfume composition distilled water was added to the window example 14: according to the following formula preparation of shampoo composition bleaching medicinal plants Extract 15 strong extract of hemp leaves 20 GAMAL SBS-11 (cleansing agent) 30% TTP as peat, 1-8% by weight of sweet medicinal plant extract and similar beneficial male skin The elasticity, and therefore the coating and penetration into the skin and medicinal plant extracts 0.1 0 parts by weight 1 5 0 0 parts by weight 5.0 G parts by weight 10. 10 parts by weight 0.1 Q parts by weight 10 .0 0 parts by weight 〇.30 parts by weight 1 0 0 .0 0 reset parts • 0 0 g 7 .5 0% by weight .0 0 g 10.00% by weight .0 0 g 15.00% by weight (please read the back first Please fill in this page for more details) -18- This paper is used in the "B Family Awards (CNS) T4 Specification (2 丨 0X297) *) 81. 4. 10,000¾ (| 〇Ministry of Economic Affairs, Bureau of Standards, Staff Consumption Printed by cooperatives 06lb〇 V. Description of the invention (17) GAMAL NO-3 (cleaning agent) Aseptina ethanol BR 0 N 0 P 0 L (preservative) chlorine Replace 92 parts of the above-mentioned shampoo TTP with water, to obtain 100 parts by weight of the extract, which can be used to replace the strong enthusiasm 1 5: Prepare the following shampoo composition horse millet extract calendula extract GAHAL SBS- 1 1 GAMAL N0-3 Aseptina ethanol BR0N0P0 L vaporized sodium water Λ 6 Η 6 2 0 .00 g 10.0 0% by weight 0.40 g 0 • 2 0% by weight 1 • 60 g 0 .8 0 reset% 0 • 04 g 0 .0 2% by weight 6 _ 0 0 g 3 .0 0% by weight 10 6 • 96 g 5 3 .48% by weight 2 0 0 • 00 g 10 0, 0 0% by weight in the fine composition, add 8 parts by weight of the shampoo of the present invention, and extracts of the leaves of other medicinal plants, hemp leaves. 1 3 · 0 0 g 2 2. 0 0 g 3 0. 0 0 g 2 0. 0 0 g 0. 4 0 g 1. 6 0 g 0. 0 4 g 6. 0 0 g 1 0 6. 9 6 g A total of 2 0 0. 0 0 g -1 9-This paper scale is used in China》 楳 楳 准 (CNS) Ή specification (210X297 Goods) 81. 4. 丨 0,000 sheets (Π) (please read the precautions first and fill in this page) Λ 6 H6 20615b V. Description of the invention (18) (please read the precautions first and then complete this page ) In 95 parts by weight of the above composition, add 5 parts by weight of TTP, to obtain 100 parts by weight of the shampoo of the present invention. Example 1 fi: Toothpaste contains 〇. (Π-ί) .1 {) 2% by weight as a concentrated peat extract, 1-10% by weight of essential oil or its composition or other fruit sesame oil, 5-10% by weight Glycerin, 0.10-10% by weight of medicinal plant extracts, and 20-35% by weight of cleaning substances dispersed in 45-60% by weight of water, and 1-2% by weight of dyes and whitening ingredients. Titanium dioxide can be used as an albino component ΤΡ Ρ itself can also be used as anti-additive sage leaves 9 Chamomile or marigold extract can be used as a beneficial and better medicinal plant extract. The preferred formula is as follows precipitated calcium monate 15 0 .00g m acid m 60 .00g glycerin 7 0 0 0 g medicinal plant extract 5.0 0 g TT P 0 .50g titanium dioxide 10.0 Og essential oil (or peppermint> lemon-like sesame oil) 5.0 Og Water 4 0 0 .0 0 g Dye-a small amount of Example 11; bath preparation: in use to obtain the peat-derived biological activity of the present invention Printed by the Employees ’Cooperative of the Central Standards Bureau of the Ministry of Economy -20- 81. 4. 10,000 sheets (1 [) This paper uses the Chinese National Standard (CNS) 4 specifications (210x297 g; it) 06ιδΰ Λ 6 Η6 5. Description of the invention (19) In the method of the product, the liquid should be converted into In the powder state, this is, and the resistance in the plug_ Some products , A certain secondary salt has the calcium contained in it, and the salt and salt produced by the salt product will be departed from it; the production of the secondary product into the chemical vapor is divided into nano-gasification structure as The gas should be 95% of the main hydrochloric acid sulfur and the physical and chemical TT. The structure is combined with the crystallizing and forming machine. There is no such a machine, etc. This is combined with the chemical machine to form a sub-amine, and the accumulation of low sugar is derived-it Slime .: Sassafras, which can be produced in the pair of salt storage baths. It is produced in the para-yin-yin salt. In the case of the benefit, the bath acid such as salt can be used as an alkene-rich salt. Based on this qualitative lanli wave material, this test was tested in the Institute of Transitology, and the Chinese Academy of Sciences was used to study the results of the research. The effect of the C fruit is 10 I. ο Xie amount In plus Ba added sex an active zn standard P0 quality: ^! Group availability of P5 oil should be as good as TT, or if it is not suitable for blocking oil, it is a good example. The research method is used for Rong Youmei, to make Rong Kemei for the bath, which is used for this purpose. The salt is used as a material and the fragrance is extracted from the hair. The head is used for the new medicine Q / Tong 2 1X, I 1 point. 0% οElectricity% of static TT resistance% Volume 3 3 (please read the back-end precautions # fill out this page) Install & Order-line. Printed by the Ministry of Economic Affairs + Central Standards Bureau KX Industrial and Consumer Cooperative The dryness is over the skin and the hair 5 collar-0 anti-05 pre ο 0% of the oil content, %% of the weight of the heavy agent Dingan and anti-corrosion,% of the amount of E3, the amount of water and r fat Zhiwu · 'The kinetic liquid is composed of benzoic acid salt containing fermented buds, ammonium chloride, and chloramine and electro-amine to prevent the anti-thrombogenic effect of the amine. Standard (CNS) A 4 specifications (210x297 cm) 81. 4_ 10,000 sheets (|!) £ 66153 Λ 6 Β6 Printed by the Beigong Consumer Cooperative of the Bureau of Standards, Ministry of Economic Affairs 51 V. Description of invention (20) Thickening of fixed dose The agent is cosmetic alcohol. The agent for preventing excessive drying of hair and skin is vegetable oil.9 It can also be used as Co-emulsifier 9 and glycerin which is easy to apply and read through the balm (the active ingredient TT 'P and medicinal plant extracts) and the reproduction of fine m can be stopped due to the acidic environment> Therefore, the fragrance of the present invention The cream contains 0. 0 1% by weight of citric acid or fumaric acid and a preservative known as BRO N 丨 0P 0L and perfume composition. The preferred formula is as follows * Alcohol solution of dimethylamine and chlorinated ammonium salt 3- 4% by weight cosmetic alcohol 3- 4% by weight T1 'P 0. 0 1 -1 0% by weight thickened medicinal plant extracts 0.0 1 -1 0% by weight glycerol 1.5% by weight vegetable oil 2.0% by weight of citric acid or fumaric acid 0.1% by weight BR0N0P 0L 0.1% by weight perfume composition 0.3% by weight distilled water to 100% by weight Example 19 Beauty face The therapeutic mud is known to have many different kinds of cosmetic preparations and the therapeutic mud is also known to have beneficial effects on the skin and the body. 9 It is believed that the mud is extracted after being obtained by a method of preparing bioactive peat-derived compositions from peat Coal can also be used for cosmetic purposes. After extraction, peat contains an active body solution that is not available in the age hydrolysis method. »Because of the pole of peat after neutralization -22- (please read back to the precautions # fill in this page ) This paper scale uses the Chinese National Sample (CNS) T4 specification (210X297 public goods) 81. 4. 10,000 »(H) Λ 6 Η6 ^ 06155 5. The description of the invention has high adsorption properties, so it proves to be valuable as a beauty mask Ingredients, in order to extract peat after Yifu has a variety of valuable ingredients, add neutral therapeutic peat and humic acid present in neutral peat, and in the method of obtaining bioactive compositions derived from peat, Separated from age-related hydrolysate, this composition was tested in the above Balneologic Institute and found to be suitable for cosmetic useThe preferred formula is as follows: post-extraction peat 1Q0. Og neutral therapeutic peat or peat 20.Og humic acid scallion 10. Og magnesium masterbatch 10. Og gasified zinc 5.0 g. Citric acid 0. lg plant extract or powdered plant material 5.0g distilled water suitable for the following arguments and explanations of the biological point of view of Yulan in the products of the present invention, that is, the biological activity and compatibility of these products For compatibility as a pharmaceutical product, the following abbreviations will be used as follows: TTP TOLPA®5 Torf preparation (Poland, ul. Mydlana 2 ', a commercial sample of Torf Co., Wroclaw) IFN is produced in cells that are invaded by the cell , For the presence of cytosine (group hormones), IFN gene is present in all cells, IFN is mainly caused by protein or glycoprotein, stimulated production-2 3-This paper scale uses the Chinese National Standard (CHS) Τ4 Specifications (210x297 public address) (please read the precautions before filling in this page) Install & Order-Line · Printed by the Central Standard of the Ministry of Economic Affairs, Migong Consumer Cooperatives 81. 4. 10,000 sheets (Ιί) Λ 6 Π 6 5. Description of the invention (22) The IFN gene of IFN The substance is called an initiator, and the method of IFN initiation is a highly unconventional and complex biochemical method; the negative and positive subnode genes that control the production of IFN have been confirmed. IFNs are sometimes called "physiological IFNs". IF N exists in nature in three main molecular forms: I FN-α (or leukocyte IFN), IFN- 彡 (silk protein IFN), and IFN -y (immune IFN). IFN-α and IFN- / S are Ι-IFN type, IFN-y is II-IFN type. The main biological activities of IFH are antiviral, antiproliferative (antitumor) and immune activity. Various Types of IFN are commercially prepared from natural and recombinant preparations, and can be used as drugs for the treatment of ulcers, viruses and several other diseases. CTL = cytotoxic T lymphocyte NK cells = natural killer cells IL-1, IL-2 is an interleukins that is known to suppress the prolonging life of T cells and other lymphocytes (including B cells). It is printed by the Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the precautions first (Fill in this page again) RPM I 1640 Tissue culture medium for growing humans and other white blood cells (abbreviation of R swe 1 1 P ark M e π 〇ria 1 I nstitute of B uffa 1 〇); FCS = fetal bovine blood (used in white blood cells Analysis, because it can contain analog-2 4-This paper scale uses the Chinese national "CH (CHS) Jia 4 specifications (210x297 male dragon) 81. 4. 丨 0,000 sheets (H) Λ 6 Η6 V. Invention description (23 ) The developmental substance of internal white blood cell action, so it needs to be tested in advance); EMCV = Cerebrospinal virus, PiC0rna virus for human non-causal mouse, which is usually used as an experimental virus in IFN bioassay; A-549 human adenocarcinoma cells 1. Due to its high sensitivity to IFN-α, cold, and y, it can be used for the biological analysis of IFN. This cell strip is recommended for WHO identification in IFN standardization; Μ TT 3-[4,5 -dimethyl Oxazol-2-yl] -2,5-diphenyltetrazolium bromide, a reagent for the determination of killed cells or cell growth by ELISA scanner in biological analysis of coefficient species (Hansen et al., J. I ηu η ο 1. M et h. 1 9 8 9, 1 1 9, 2 0 3-2 1 0); L929 mouse cells Bar, generally used for the analysis of mouse IFN and human or mouse TN P; TO ulcer necrosis factor, bovine cells, (very small protein, very sensitive to protein level enzymes), made of single cells and giant cells (TNF- ct is also known as the cachexia factor that causes cachexia in humans and animals); Printed by the Industrial and Consumer Cooperatives, E3, Bureau of Standards, Ministry of Economic Affairs (please read the back-end precautions # fill out this page) with LPS (fat Glycans), viruses, and many other reagents after being stimulated, are very toxic to many viral infections and new cells. They can also be used as growth factors of silk proteins and are linked to inflammatory reactions. Related types of TNF-β ( Lymphocytes are mainly produced by T cells and certain other cells; PBL terminal blood leukocytes, normal human leukocytes obtained from healthy blood donors, are derived from " Barbie layer " (between red blood cells and plasma Boundary-2 5-This paper is used in the "Mingjia" Standard (CNS) Ή Specification (210X297 mm) 81. 4_】 0,000 sheets (H) Printed by Beigong Consumer Cooperative of Central Bureau of Standards, Ministry of Economic Affairs Λ 6 Π 6 V. Description of the invention (2 4) Face phase). The response of various PBL donors to various cytoplasmic initiators depends on the detriment of the donor. The high-responders and non-responders confirmed that they were related to the response of PBL to TTP. When using weak initiators than using strong initiators, such as viruses, you can see the difference in the response of the body to IFN or TNF inducers. This is because the response to weak initiators is "all or no" Viruses almost always trigger a detectable amount of cytoplasm. Tolerance of the initiator: Also known as a sub-reactive state. Weng occurs after a single dose of the initiator is administered, for example, PBL is exposed to the initiator (such as a virus ) After 20 hours; the cell stops further producing IFN. The sub-reactive state is often held for about 7 days. It may be complete or partial. This reactivity makes the therapeutic application of strong initiators difficult and / or ineffective. Weak IFN initiator It also does not cause a sub-reactive state or its tolerance is small. Many natural medicines are extracted from medicinal plants with disease-free properties. Β ΤΤΡ is one of them. Β ΤΤΡ changes many in vivo and in vitro. Immune function. It initiates a balanced immune function and activates all the actuator pathways (CD4 additives, weak CD8 inhibitors, CTL, {JK cells, and active giant antibiotics) with non-specific capabilities, and It is not toxic to normal cells. TTP has the effect of restoring health in the treatment of general trauma. The low dose of TTP can withdraw the production of weak thorns · stimulation IL · 1 and IL-2. The high dose can inhibit the synthesis of bovine cells. Relative test with TTP is carried out according to the following methods: -26- The standard size of this paper is CNS Τ4 specifications (210X297mm) 81. 4.〗 0,000 sheets (Η) (please read the back And the precautions #fill this page) Installation · Line-^ 06155 Λ 6 Η 6 The central sample of the Ministry of Economic Affairs is printed by the Zhengong Consumer Cooperative 31. V. Description of the invention (25) PBL obtained from healthy blood damage donors Ammonium chloride treatment and purification. The culture medium is RPMI 1640 plus 1096FCS. Cultivate about 8X106 cells / ml at 37 ° C and 5% C02 for 20 hours. The bacterial cells and white matter have anti-filterable virus activity. Pseudomonas in human A549 cells The cytopathic effect inhibition analysis also uses the MTT method to measure the killed cells. The activity is measured in L929 cells. In order to determine the IFN type, separate IFN samples are treated with different anti-IFN serum for 1 h. Anti-filtering virus Comparing the active ingredient with the untreated preparation. Tests have shown that TTP stimulates the production of endogenous interferons (IFNs) and tumor dying factors (TNF). This response is dose-dependent. The 7 analyzed commercially available products of TTP have comparable biological activities, such as immune inhibitors And bovine cell initiator.-It has been found that there are many variations in the response of different blood donors' white blood cells to TTP. Various doses of PBL have been found to be anti-free. This can reflect the background of the deportation. The use is powerful Multi-source antiserum, such as anti-IFN-a (Cantell), anti-IFN-α Ly (Namalwa) (from K Fantes), and anti-IFN-y (Cantell) were neutralized and treated with TTP for 20h at Anti-filtering virus activity of PBL on the surface. The results of the neutralization analysis were found to be similar to the fingerprints of the individual blood donors. In other words. The ratio of IFN type produced by all is very variable. The separation of PBL into sticky and unsticky parts can enhance the induced cytoplasmic synthesis. The secondary response (tolerance) of NDV to IFN inducement is at TTP -2 7-(please read the precautions before filling out this page) Binding-Order 'line. This paper is used for standard B Η home sample standard (CNS) T4 specifications (210X297) *. Owed 10,000 sheets (Π) Λ 6 It 6 Printed by the Beigong sample bureau of the Ministry of Economic Affairs Beigong Consumer Cooperative Co. V. Invention description (26) It was found to be minimal or absent 20 hours after stimulating PBL. In all 7 groups of PBL tests in humans, such as IFN and INF initiators, it has been found that Tong is active in initiating IFN and / or INF. The optimal TTP concentration for IFN triggering is 30-100 // g / ml, and for TNF triggering is 100-20G # g / nil. The 2Q0 # g / ml dose is less toxic to PBL, but TNF synthesis is faster than INF and occurs faster than moderate cytotoxicity. The foregoing conclusion is that the experimental subject of the active body in TTP Pharmaceuticals was obtained from the immunologically active part of the extract containing organic, primary sugar, amino acid, uronic acid, humic acid and peat containing microelement mineral salts Copies. The LDso image in animals > 2400 mg / kg per os〇 TTP was not found to be mutagenic, toxic to germ cells, toxic to embryos, and produce deformed or carcinogenic activity. ΤΤΡ shows no allergenic properties and no local stimulating activity. Treatment is suitable for chronic respiratory diseases and repeated inflammation of the respiratory system. Schedules 1-24 are related to various biochemical tests, such as toxicity, blood, and immunity tests. These tables show and provide biologically relevant information about the affinity and biological activity of TTP. It is worth noting that the concentration of the active ingredient in the medicament, as shown in item 13 of the patent application, can be higher than that of the maintenance ingredient (as shown in item 14 of the patent application). Tong is based on the following reasons: Unit preparation_pharmaceutical preparation, in which the content of the active ingredient is under strict control, for example, in the tablet, the concentration is determined by the size of the tablet containing the effective daily dose (or part) of the active ingredient. -2 8-(please read the back-end precautions # fill out this page). Binding. Thread-This paper is used in the "National Sample (CNS) Τ4 specification (210X297 male dragon :) 81. 4. 10,000 Zhang (| [) Λ 6 Η 6 V. Description of the invention (27) The active ingredient of the active ingredient, such as TTP, in the granules filled in the bursa, preferably only 5 wt%, to achieve a sufficient tablet size, and Make the capsule machine suitable for administration. Another reason is that most drugs are administered orally, and the active ingredients are distributed throughout. Even if it reaches the skin cells at a very low concentration, the shadow of treatment is notable. Furthermore, the maintenance composition-different from the medicament-is used in a relatively uncontrollable amount, and the regional coating penetrates into different cells at different rates. . Some compositions, such as shampoo, are washed off almost immediately. The contact time with the hair or body is short, and relatively contains more effective ingredients; others are coated many times a day, so they should have a low Active ingredients. Finally, as in the case of tooth buds, it is in contact with the mucus component in the mouth. The penetration of the active component is easier than passing through the skin, and the concentration of the active component can be lower. (Please read the precautions before filling in this page) Printed by the Employee Consumer Cooperative of the Department of Economics, Biyang, Ministry of Economic Affairs -29- 81. 4. 10,000 sheets (| [) This paper standard is being used with ease (CNS) Ή specification (210x297 g; !! :) λ 6 η 6 Five Λ Description of invention (28) The Ministry of Economic Affairs 剮 央 梂 貢 局 A Gong Xiaokan cooperative cooperative seal 51 O rH Cs3 «〇oc〇C〇o c- —. Csj «~ H in oo O C3 C => C3 ao O CD m age httf b〇oo C3 OO € 3 C3 C3 QG CD C3 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 +1+ 1 + 1 + 1 c〇ς〇o inch ITD t > * CO C5 CM Cs. BU CO ιο m Η 1 ιο lO ΙΟ UD iro itd t- o to < x > CD CD O C3 C3 C = J CP O cd cr > O CD bow cn ¢ 0 ^ CS3 inch CO cn CO -LJ m inch CO inch ΙΛ ΙΟ CO 00 〇t—t CO State hiding CO CD iH CO Cs3 cot-H < N CQ co • Ν 娜 b 〇s— / + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 m CD oo co CO CD 〇〇co in co xn csi 00 t— ◦ 〇c〇L〇卜卜 co < xS o〇t >-Ling eo co tn in BU CO in in rh CO O CD r- »〇〇CD CQ CJ CO ψ · 4 i 1 —CO y ^ -i to inch 〇CO CO CNJ CD — Professional CD C3 CD O CP o CD OC = > CD CD < = > Shovel Ο + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 05 CQ < 〇co ^ o? cn 00 ^ to inch CD ◦ C3 — oo 00 c〇OO OO CD «r-4 O CD C? C3 CD 1—i O — Warm Q-. * CL · C = > l >-CD Bu o Bu ◦ Bu Q Bu O Bu eH Thai CL, .b〇a CD CP < = > CP o 6 " »_ •-• m e-η C'J IT3 CD CJ to« b〇 昶 m ix < m —30— (please read the precautions before filling this page) Binding. Thread-This paper scale is easy to use Chinese Η family tree (CNS) > P4 specification (210 father 297 male dragon) 8L 4.] 0,000 sheets (H) 5. Description of the invention (29) male m Λ 6 Π 6 Printed by the XX Industrial Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs

-31- 本紙尺度逍用中as家楳毕（CNS)甲4規格（210x297公;¢) (請先閲讀背而之注意事項洱堝寫本頁) 裝· 線. A 6 ΙΪ 6 五、發明説明（30) 經濟部屮央標準局貝工消t合作杜印Μ ο — CNJ f—« Ο ο in r-H ΙΟ T-H O CD oa»—< C3 O co cn CM O C3 in co co in G C=9 <〇 CO t-h ς〇 cr> o +1+1 +1+1 CO CT3 +1+1 co +1+1 CO ^ +1+1 +I+I ^ X CSJ »-Η ΙΟ ΙΟ OO CO ΙΛ lO 寸o ITD lO ιλ m 寸 CO ura ΙΛ卜 寸ITD ς〇 却ς〇 CD CD 0〇 CD LO t— C3 O 03 05 <73卜 C3 *-H CO寸 <〇 σί o o o oo CD C5 CN3 t-H CO CO CO卜 t-H SI +1+1 Cn3 C3 +1+1 +1+1 +1+1 +1+1 +I+I m ΙΛ lO ◦ CD *^r co OJ tr— X CO CO CO t— CO ΙΛ r-H CO 05 CD \T7 CO Ν in t— CO ιο in 卜〇〇 -H C3 OO — 03 CO m 躲 m 0〇 CO 〇〇 CO <0 CQ CS3 CO CO 〇 ^ CD ·§ O CD CM C3 r- H v—H 寸CN3 CsJ Cs3 +1+1 +1+1 +1+1 +1+1 +1+1 +I+I -¾ 〇〇卜 CO CO CD t— c— lO co 0〇 CO CO CO CO 却¢0 CO CO co CO 嫌 寸CQ —CO 却CO ΙΛ -r—* CO 05 co uZ L·次 CO CO呀 1 CN3 CO CO CNJ CO «〇 CD m CD O CD O CD CD o o C3 O C3 — □ Ρ_ 坊ta〇 +1+1 +1+1 +1+1 +1+1 +1+1 H+l 0〇 esj — »—< lO CO f CN3 CO €〇 CM '―* t-H 4 〇 CD CO — *—1 〇〇 oo CNJ 1—» »~H 1—H c— CO CSJ CD > 4 r- < E-η Ε-Η o t— CD C— C卜 CD t— o t— <=? c- m 邾 CD CD o CD CD CD ffC no o CsJ IT3 <=3 CvJ IT3 co m *1 '届 U-i -32- (請先閲請背而之注意事項再项寫本頁) 裝- 線- 表紙張尺度逍用中《國-家榣毕（CHS)甲4規格(210X297公;ft) 五、發明説明（31) 〇 2 90 10 ά Η 02-31- This paper scale is used in the asa family (CNS) A 4 specifications (210x297 g; ¢) (please read the precautions on this page to write this page) Installation · line. A 6 ΙΪ 6 5. Invention Explanation (30) Beigong Consumers' Cooperation with the Bureau of Standards, Ministry of Economic Affairs, Du Yin Μ — CNJ f— «Ο ο in rH ΙΟ TH O CD oa» — < C3 O co cn CM O C3 in co co in GC = 9 < 〇CO th ς〇cr > o + 1 + 1 + 1 + 1 CO CT3 + 1 + 1 co + 1 + 1 CO ^ + 1 + 1 + I + I ^ X CSJ »-Η ΙΟ ΙΟ OO CO ΙΛ lO inch o ITD lO ιλ m inch CO ura ΙΛ Bu inch ITD ς〇 but ςCD CD 0〇CD LO t— C3 O 03 05 < 73 Bu C3 * -H CO inch < 〇σί ooo oo CD C5 CN3 tH CO CO CO Bu tH SI + 1 + 1 Cn3 C3 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + I + I m ΙΛ lO ◦ CD * ^ r co OJ tr— X CO CO CO t— CO ΙΛ rH CO 05 CD \ T7 CO Ν in t— CO ιο in 卜 〇〇-H C3 OO — 03 CO m hide m 0〇CO 〇〇CO < 0 CQ CS3 CO CO 〇 ^ CD · § O CD CM C3 r- H v—H inch CN3 CsJ Cs3 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + I + I -¾ 〇〇 卜 CO CO CD t— c— lO co 0〇CO CO CO CO ¢ 0 CO CO co CO CZ —CO but CO ΙΛ -r— * CO 05 co uZ L · CO CO 1 1 CN3 CO CO CNJ CO «〇CD m CD O CD O CD CD oo C3 O C3 — □ Ρ_ 坊 ta〇 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 H + l 0〇esj — »— < lO CO f CN3 CO € 〇CM '― * tH 4 〇CD CO — * —1 〇〇oo CNJ 1— »» ~ H 1—H c— CO CSJ CD > 4 r- < E-η Ε-Η ot— CD C— C 卜 CD t— ot— < =? c- m 邾 CD CD o CD CD CD ffC no o CsJ IT3 < = 3 CvJ IT3 co m * 1 'session Ui -32- (please read the precautions before writing this page) install -Thread-"Paper-Family Congratulations (CHS) A 4 Specification (210X297 g; ft)" in the free use of surface paper scale V. Description of invention (31) 〇2 90 10 ά Η 02

0+ιΖΙΟ 0+15 0+ιΖΙ 0+IS ο+ιεζ 0+IU ζο το S 10 10 60 09 io o+lgs o+ii卜 0-H90o+ls o+ls 10s 60 10 sso Λ 6 Π 6 δ·0+ι9ε·0 εο·ο+ιζε·ο (3V3H) _«dll 0.00 + ιZΙΟ 0 + 15 0 + ιZΙ 0 + IS ο + ιεζ 0 + IU ζο το S 10 10 60 09 io o + lgs o + ii Bu 0-H90o + ls o + ls 10s 60 10 sso Λ 6 Π 6 δ · 0 + ι9ε · 0 εο · ο + ιζε · ο (3V3H) _ «dll 0.0

SISI

OS 0.0OS 0.0

ο+ιειο o+looi-o+ls o+lg O+IVCVJ G+I9S Ιο·ο+Ιοε·ο (請先間讀背而之注意事項#填寫本頁) s 10 10 ss s 裝· 0+109.0 si-0o+loso o+ls 0+I6S0 0+19Z.Oο+ιεο g 10 CJO 000 00 s 0+120o+ls o+lg 0+lISO 0+1¾ 0-ΗΪ9 o+lsro 訂_ 線- 10s 91 10 TO 80 0+1910o+ls o+lsoo 0+150 ο+ιεζ o+lCJi S,0+I9S,0 經濟部屮央標準而s：工消ff合作社印製ο + ιειο o + looi-o + ls o + lg O + IVCVJ G + I9S Ιο · ο + Ιοε · ο (please read the back and the precautions # fill in this page) s 10 10 ss s installed · 0+ 109.0 si-0o + loso o + ls 0 + I6S0 0 + 19Z.Oο + ιεο g 10 CJO 000 00 s 0 + 120o + ls o + lg 0 + lISO 0 + 1¾ 0-ΗΪ9 o + lsro Order_ line- 10s 91 10 TO 80 0 + 1910o + ls o + lsoo 0 + 150 ο + ιεζ o + lCJi S, 0 + I9S, 0 Ministry of Economy Standards and s: Printed by Gongxiaoff Cooperative

Iril 伸聃 sff ίιΙΒΒ & te 黠a,? £ 本紙5良尺度边用中β«家楳準（CNS)TM規格（210x297公;«：) A 6 Π 6 五、發明説明（32) 經濟部屮央標準局G5工消t合作社印製 表5慢性赛性，ΤΤΡ口服投藥對兔子血液參數之影镨 性 別 TTP 劑量 g/kg 測 試 天 數 檢査 參數 血红素 (fflg% ) 血球容積 (%) 白血球 X 10- 3 红血球 X 10" 6 Μ 0.0 0 12.2±0.05 38.2±1.71 9.33±0.79 5.10±0.56 7 12·3土0.15 40.7±0.33 9.39±1.18 6.34±0.23 6 3.0±0.35 41.7±1.30 9.58±1.12 7.32±0.70 12 13.5±0.19 40.7±0.67 11.23±1.10 6.30±0.46 Μ 50 0 12.9±0.55 35.7±1.82 7.52±0.78 5·14±0.47 0 6 13.3±0.35 41.0±2.10 8.08±1.17 6.38±0.11 12 13.7±0.11 39.3±0.94 9.36±1.01 6.19±0.19 Μ 150 0 14.20±0.21 36.7±1.81 8.19±0.16 5.34±0.16 3 11.05±0.26 38.5±1.53 8.83±0.78 5.68±0.40 6 12.40±0.63 37.3±1.45 8.18±0.06 6.84±0.10 12 13.70±0.32 39.0±0.68 8.24±0.04 6.54±0.54 F 0.0 0 12.6±0.27 40.2±0.83 7.07±1.16 5.63±0.17 3 12.1±0.23 39.8±0.72 8.16±1.01 5.74±0.12 6 12.4±0.86 42.3±1.20 9.78±1.69 5.86±0.24 12 12.5±0.87 37.7±2.18 10.90±2.16 4.60±0.29 F 50 0 0 13·2±1·20 35.0±1.70 7.44±0.98 5.47±0.60 0 6 13.0±0.55 39.3±1.20 7.25±0.96 7.08±0.94 12 12.8±0.21 37.7±4.33 9.31±0.35 6.02±0.32 F 150 0 15·2±1·15 38.3±1.40 8.50±0.54 6.09±0.08 3 13.1±1..10 47.0±2.80 8.10±0.76 5.85±0.57 6 12„.5±0..82 41.0±1.15 6.85±0.31 5.61±0.30 12 13.1 ±0.70 41.0±1.00 8.15±1.68 5.92±0.13 -34- (請先閲讀背而之注意事項#填寫本頁) 裝. 訂_ 線- 本紙張尺度逍用中a«家楳準（CNS)甲4規格(2丨0x297公釐) 五、發明説明（33) Λ 6η 6 經濟部屮央榣準局貝工消t合作社印製 CO <〇却 CO QO C3 co ΙΛ CD 卜o +1 ¢0 <〇 to CO C5 ♦—* ΙΓ3 CO CM 0〇 1-H +1 CSJ却 in <=5 1-3 CQ 卜o +1 a *-h —+1 0〇 t-H +i CQ t— lO t— m oo t— 1 CO CO 卜oo id CZ> t*- ◦ +1 +1 +1 m m 馬 m CO C〇 CO CD CO 03 0〇 *寸卜 in C75 〇 · « * CO oo ^+1 CO oo -H CO C3 卜+1 ΙΛ *—· 肋 trj CO cd * cn卜 CT3卜 <-3 *°+l ^+1 co+| ΙΛ寸 寸03 CS3 t— CJ2 CO «〇+丨 CD C5 o ^+1 ^+1 於 翎 ¢0 17.6 ±3.0 CJ CD 〇 « · 餐f-卜 ^+1 l〇 — 0 · · 杨《Ο 05 • ^+1 ¢ + eo η eo \o ^ 00卜 β * · «- CO CO 〜+1 〇 · · 祷Csj卜 •δ-* —+1 ^+1 » .來 o C5 ¢0 寸 ^+1 ^ '-I 00 t-—+1 to 05 ΙΛ ^ —+1 CO β>α C3 t— t-H t-H t>- CO o o · · 餐H fH -¾¾ +1 +1 +1 4d^ •B-g CO C3 CO — esj h +1 cn os 一 o 04 !>· o * · * — C3 CM CD +1 CO to o · · 祷—c coi1 CS3 CD +1 G CO IT3 OO 對照组 1 ·1 PBS i.v. r—< tk〇 Jti'bO · Jlf'So * g-π ·*-» ^mm>^ E-H to -f-< 級»脷_»4|塚^90.0^相«出绽匪辄« 。 躲撕i)<(wsi+i-Ng. 0>〇<相·Ι}?:捉！|^&1笵寐眾 * «9 兹SSSdiX 9 Η<ε 班濂Sfdii ε @n!«dll ο 挺珐賠筇籲趙雔3£liM c (請先閲誚背而之注意事項再填寫本頁) 裝- 訂· 線-Iril Extend sff ίιΙΒΒ & te 黠 a ,? £ This paper has 5 good-size edge-use medium β «Household Standard (CNS) TM specifications (210x297);« :) A 6 Π 6 V. Invention description (32) Ministry of Economic Affairs G5 Gongxiaot Cooperative of the Central Bureau of Standards printed the schedule 5 Chronic race performance, oral administration of TTP on rabbit blood parameters, praseodymium sex TTP dose g / kg test days check parameters heme (fflg%) blood cell volume (%) white blood cells X 10- 3 red blood cells X 10 " 6 Μ 0.0 0 12.2 ± 0.05 38.2 ± 1.71 9.33 ± 0.79 5.10 ± 0.56 7 12 · 3 ± 0.15 40.7 ± 0.33 9.39 ± 1.18 6.34 ± 0.23 6 3.0 ± 0.35 41.7 ± 1.30 9.58 ± 1.12 7.32 ± 0.70 12 13.5 ± 0.19 40.7 ± 0.67 11.23 ± 1.10 6.30 ± 0.46 Μ 50 0 12.9 ± 0.55 35.7 ± 1.82 7.52 ± 0.78 5.14 ± 0.47 0 6 13.3 ± 0.35 41.0 ± 2.10 8.08 ± 1.17 6.38 ± 0.11 12 13.7 ± 0.11 39.3 ± 0.94 9.36 ± 1.01 6.19 ± 0.19 M 150 0 14.20 ± 0.21 36.7 ± 1.81 8.19 ± 0.16 5.34 ± 0.16 3 11.05 ± 0.26 38.5 ± 1.53 8.83 ± 0.78 5.68 ± 0.40 6 12.40 ± 0.63 37.3 ± 1.45 8.18 ± 0.06 6.84 ± 0.10 12 13.70 ± 0.32 39.0 ± 0.68 8.24 ± 0.04 6.54 ± 0.54 F 0.0 0 12.6 ± 0.27 40.2 ± 0. 83 7.07 ± 1.16 5.63 ± 0.17 3 12.1 ± 0.23 39.8 ± 0.72 8.16 ± 1.01 5.74 ± 0.12 6 12.4 ± 0.86 42.3 ± 1.20 9.78 ± 1.69 5.86 ± 0.24 12 12.5 ± 0.87 37.7 ± 2.18 10.90 ± 2.16 4.60 ± 0.29 F 50 0 0 13 · 2 ± 1 · 20 35.0 ± 1.70 7.44 ± 0.98 5.47 ± 0.60 0 6 13.0 ± 0.55 39.3 ± 1.20 7.25 ± 0.96 7.08 ± 0.94 12 12.8 ± 0.21 37.7 ± 4.33 9.31 ± 0.35 6.02 ± 0.32 F 150 0 15 · 2 ± 1.15 38.3 ± 1.40 8.50 ± 0.54 6.09 ± 0.08 3 13.1 ± 1: 10 47.0 ± 2.80 8.10 ± 0.76 5.85 ± 0.57 6 12 „.5 ± 0..82 41.0 ± 1.15 6.85 ± 0.31 5.61 ± 0.30 12 13.1 ± 0.70 41.0 ± 1.00 8.15 ± 1.68 5.92 ± 0.13 -34- (please read the back-end precautions # fill out this page) to install. Order _ line-this paper size is easy to use a «Jia Shu standard (CNS) A 4 specifications (2 丨 0x297mm) Fifth, the description of the invention (33) Λ 6η 6 CO &O; CO QO C3 co ΙΛ CD Bu o +1 ¢ 0 < 〇to CO C5 ♦ — * ΙΓ3 CO CM 0〇1-H +1 CSJ but in < = 5 1-3 CQ bu o +1 a * -h — + 1 0〇tH + i CQ t— lO t— m oo t— 1 CO CO oo id CZ > t *-◦ +1 +1 +1 mm ma CO C〇CO CD CO 03 0〇 * inch Bu in C75 〇 * «CO oo ^ + 1 CO oo -H CO C3 BU +1 ΙΛ *-· rib trj CO cd * cn BU CT3 bu < -3 * ° + l ^ + 1 co + | ΙΛinch inch 03 CS3 t— CJ2 CO «〇 + 丨 CD C5 o ^ + 1 ^ + 1 Yu Ling ¢ 0 17.6 ± 3.0 CJ CD 〇« · Meal f- 卜 ^ + 1 l〇— 0 · · Yang "Ο 05 • ^ + 1 ¢ + eo η eo \ o ^ 00 Bu β * ·«-CO CO ~ + 1 〇 · · Prayer Csj Bu • δ- * — + 1 ^ + 1 ». 来 o C5 ¢ 0 inch ^ + 1 ^ '-I 00 t -— + 1 to 05 ΙΛ ^ — + 1 CO β > α C3 t— tH tH t >-CO oo · · meal H fH -¾¾ +1 +1 +1 4d ^ • Bg CO C3 CO — esj h +1 cn os one o 04!> O o · · * — C3 CM CD +1 CO to o · · prayer—c coi1 CS3 CD +1 G CO IT3 OO control group 1 · 1 PBS iv r— < tk〇Jti'bO · Jlf'So * g-π · *-»^ mm > ^ EH to -f- < grade» 脷 _ »4 | Tomb ^ 90.0 ^ phase «Breakout Bandit«. Hide i) < (wsi + i-Ng. 0 > 〇 < 相 · Ι) ?: Catch! | ^ &Amp; 1 笵 眠 众 * «9 兹 SSSdiX 9 Η < ε Ban Lian Sfdii ε @n! «Dll ο Tingfa pays for Zhao Zhao 3 £ liM c (please read the precautions before filling in this page) Pack-Order · Thread-

本紙51尺度逍用中《 »家樣準（邙s)〒4規格(210x297公龙)This paper 51 scales for "Xiao Family Standard" (邙 s) 〒 4 specifications (210x297 male dragon)

^06iuS Λ 6 II 6 五、發明説明（3句 a m m m^ 06iuS Λ 6 II 6 V. Description of the invention (3 sentences a m m m

m m a 苌 I e-» 赵 ΠΠ 級 m 馬 B3 荽豳 frag mm 翎i «25 ^ Wr Mm m a 苌 I e- »Zhao ΠΠ level m horse B3 豽 豳 frag mm 翎 i« 25 ^ Wr M

SI 級 Λ! dd 农Ηπ N 經濟部屮央標準局E：工消1V合作杜印製 m e-< i t*H CQ t- mSI level Λ! Dd Agriculture Ηπ N Ministry of Economic Affairs, Central Bureau of Standards E: Industrial Consumers 1V cooperation du printing m e- < i t * H CQ t- m

ii 撕 3 ΐι ί $ OP^SSJ 11 wsots 3,1!SSH?J g'issl^du 〇 焰毪®瓒®饀糂S u •躲菘《铖蒗 e (請先閲請背而之注意事項孙填寫本頁) 裝- 本紙张尺度逍用中SB家標準(CNS)〒4規格(210X297公¢) 五、發明説明 35) Λ 6 Π 6 經濟部屮央標準局只工消伢合作社印Μ 級鋰馬黠Λι逛脃班s_dllΞ500槲 H< H< CO CO CNJ CO cn CO tl〇 +1 +1 +1 +1 +1 c- CM τ" Ί 卜 卜 其◦ '. '-Η 扯 <nK in CO CM 寸 CO CO »—1 b〇 m ii * 窣 * CO O 00 00 o cd α ΙΛ H< C^3 c>a CO CO to CO CO • 11 CO O-t 寸 +1 +i +1 +1 +1 6-^ e-· iflP ilK t— 03 CO CO Csi CN3 1 CD c— t— csj 卜 CO 章 o 拿 H< 寸 CN3 CNJ CO 寸 CD CO 05 CO <=> t、 +! +1 +1 +1 +1 «ton ijtK <〇 ◦ CV3 CD cn LO CsJ n CO lO *—< CUD 馬 CO CO · < T—H 1 曰II * 拿 * CD C ω CD 〇〇 CO CO —H — CU e-· H< CS3 CO CO CO ·. _ t 叶 cn CO H 寸 +1 +1 +1 +1 +1 e-H Czu 4fiC w o cq 〇〇 ? c«a CT5 CJ3 LTD 0¾ 卜 c〇 〇4 r—4 in —H CO CO CN3 H< xo 绽 +1 +1 +1 +1 +1 M CO to 〇〇 CO ¢0 CO in> CO ITD 睦 H< c— ίο CO in «rr ITD 〇〇 CO 1f*n 寸 +1 +1 +1 +1 +1 Μ· c- Cs3 〇〇 CD c— CO 卜 *'··< CO 〇0 CO ΙΟ ITD CM 圈嫌截 1 ^ CO lO cn -37- 本紙張尺度逍用中Β Β家樣準（CHS) Τ4規格（210X297公;《:) (請先閲讀背而之注意事項再填寫本頁) 裝- 舔 m Umil ΡΠ m m CL m菰 Η 訂_ 線- 五、發明説明 Λ 6 Π 6 經濟部屮央標準局E：工消#合作杜印製ii rip 3 Ιι ί $ OP ^ SSJ 11 wsots 3,1! SSH? J g'issl ^ du 〇 yan 毪 ® 铒 ® 饀 糂 S u • Hide the 揘 《铖 蒗 e (Please read the precautions first Sun fills in this page) Packed-The SB family standard (CNS) 〒 4 specifications (210X297 public ¢) in this paper standard for easy use V. Description of invention 35) Λ 6 Π 6 The Ministry of Economic Affairs ’Bureau of Standards and Standards only prints at the Cooperative Society Class Lithium Λι wandering class s_dllΞ500 Mice H < H < CO CO CNJ CO cn CO tl〇 + 1 +1 +1 +1 +1 c- CM τ " Ί 卜卜 其 ◦ '.' -Η pull < nK in CO CM inch CO CO »—1 b〇m ii * 窣 * CO O 00 00 o cd α ΙΛ H < C ^ 3 c > a CO CO to CO CO • 11 CO Ot inch +1 + i +1 + 1 +1 6- ^ e- · iflP ilK t— 03 CO CO Csi CN3 1 CD c— t— csj Bu CO chapter o take H < inch CN3 CNJ CO inch CD CO 05 CO < = > t, +! +1 +1 +1 +1 «ton ijtK < 〇◦ CV3 CD cn LO CsJ n CO lO * — < CUD MA CO CO · < T—H 1 Yue II * take * CD C ω CD 〇〇CO CO —H — CU e- · H < CS3 CO CO CO ·. _ T leaf cn CO H inch +1 +1 +1 +1 +1 eH Czu 4fiC w o cq 〇〇? c «a CT5 CJ3 LTD 0¾ b c〇〇4 r—4 in —H CO CO CN3 H < xo + 1 + 1 +1 +1 +1 +1 M CO to 〇〇CO ¢ 0 CO in > CO ITD Mu H < c— ίο CO in «rr ITD 〇〇CO 1f * n inch +1 +1 +1 +1 +1 Μ · c- Cs3 〇〇CD c— CO 卜 * '·· < CO 〇0 CO ΙΟ ITD CM circle cut off 1 ^ CO lO cn -37- This paper size is easy to use Β Β home sample standard (CHS) Τ4 specifications (210X297 public; ":) (please read the precautions before reading Fill in this page) Outfit-lick m Umil ΡΠ mm CL m m 揰 Η Order _ line-V. Description of invention Λ 6 Π 6 Ministry of Economic Affairs Bureau of Central Standards E: 工 消 # 合作 杜 印制

* CM CN3 to H< H< ψ—i CSJ t-H *-H • c- +1 +1 +1 +1 +1 b〇 〇 i〇P • CO CO • io in • CO cn o ml " a * 拿 * s eo CO QO CS3 CS3 ao Ε-» H< 寸 a +1 C5 +1 o +1 ί-H +1 «-Η +1 3ΓΚ CO a S CQ CN3 t-H ΙΛ tao o 5 * CO 兮 « s 拿 CO 〇o 〇o ira H< H< +1 CS3 +1 o +1 〇 +1 +1 bo CD jjei 一 朱 m C3 C<J o c=> CD 〇 o LO g1 " a m * 拿 拿 O m σΐ 〇〇 OO CS3 s 堪 IK o ο f—4 »—H 敢 寸 +1 +1 +1 +1 +! i<lC TO § ο s T—< 00 CO ΙΓ3 CD CO g 卜· 兮 CNJ *»4 C=> r-H CD r-H »-H 卜· +1 +1 +1 +1 +1 绽 m C^l 卜 s CO in CO CO m CO 00 c— m H< t-H o *—< C3 寸 +1 +1 +1 +1 +1 城 to CO CS3 00 tfi o <〇 CO s CO § 1 &,m s阁嫌 CO lO l> 03 CNJ —38- 本紙張尺度Α用中BID家榣準（CNS)T4規格（210X297公;it) (請先閲讀背而之注意事項洱蜞寫本頁) 裝- .is ^ 線- Λ 6 Π 6 五、發明説明（37) 經濟部屮央橾準扃A工消费合作杜印製 ΠΡ 50 Bg/kg.天 η = 10 血球凝集素，升之-l〇g2 第4天 第7天 3.80±0.87" 4.90±0.74" 2.30±1.41 5.33±0.74" 0.55±0.83 2.55±0.68** 0.00 4.33±1.24 1.55±1.49 4.30±1.26 ΠΡ 10 mg/kg.天 , η = 10 第4天 第7天 3.20±0.87** 5.90±1.70β 2.20±0.97 5.70±1.1(Γ 0.60±0.80 2.50±1.1Γ 0.30±0.64 3.25±0.96 1.11±0.99 4.40±1.35 m 第4天 第7天 1.75±0.60 6.37±1).85 2.50±0.70 6.12±1.16 1.00±0.89 3.80±1.09 0.40±0.48 3.66土\24 0.80±0.97 3.80±0.76 TTP — 週内投 藥次數 CO 1〇 卜 03 04 -li ^ (請先閲讀背而之注意事項再填寫本頁) 裝· 訂· 線. 本紙5t尺度遑用中9國家樣毕（CNS)<P4規格(210x297公;¢) Λ 6 Η 6 五、發明説明（38) 表11 ΤΤΡ之免疫效果（土 SI)) TTP 劑量 mg/kg η n PFC/106 脾細胞 第4天 %E-薔薇體 第4天 血球凝集素# 19S+7S 型 第4天 血球凝集素" 7S型 第7天 對照組 30 469 13.6 5.4 8.2 ±111 ±3.2 ±1.1 ±1.8 X X 0.5 10 997 15.6 6.8 8.4 ±139 ±1.4 ±1.0 ±1.1 X X X X 2.5 10 839 20.3 6.9 9.7 ±177 士 4.1 ±1·0 ±1.4 X X X X 5.0 10 746 23.2 7.2 9.8 ±129 ±4.7 ±0.6 ±1.4 X X X X 10.0 10 795 18.4 8.3 10.4 ±129 ±4.0 ±1·8 ±1.1 X X 25.0 10 560 16.3 &·1 9.3 ±145 ±2.5 ±1.1 ±1.1 50.0 10 400 14.7 5.3 6.7 ±57 ±4.0 ±1.0 ±1.9 X X X 100.0 10 375 11.3 5.1 5.7 ±67 ±2.2 ±0.8 ±1.6 X X X 250.0 10 305 9.5 4.8 5.3 ±67 ±2.0 ±1.1 ±1·7 (請先閲讀背而之注意事項洱碭寫本頁) 裝· 線. 經濟部中央櫺準局ex工消tv合作杜印31 X在總比較Q.Q5下之統計學重要變數（學生t-測試) * 升之-l〇g2 " -40- 本紙張尺度边用中國81家標毕（CNS)T4規格（210x297公«：) Λ 6 Π 6 五、發明説明（39) 經濟部中央櫺準局Ε：工消费合作杜印製 ««dli-Nu^εΗ<φΖΙ Η< Μ bC co CO 〇0 * CO CM CD C3 *寸〇 C〇 LO 〇 Ο — CO o〇 t-H 〇〇 t~H CT3 t-H 05 CN3 ώ j t-η o〇 »—« m m m mil/ 聊 +1 +1 +1 +1 +1 +1 铝 &! CO * * ο 00 c〇 〇卜 CD mo 呀CO CJ5 OO CQ αά 截 + CT3 t-H 03 τ—I O t-H 03 ·*—i O y—> 0〇 t-H CO zn cn »-H +1 +1 —+1 +1 —+1 +1 <N ΰιΟ CO C5 CO 03 H lO CO 00 CD c^l C<J Ο r_H CO ◦ CD H O C3 O t-H •N +1 +1 +1 +1 +1 +1 m m CO 卜CO r*H *— * i-Η O〇 crs t>* 寒 CO切 H< 雜 + LO t-H C〇 r—1 D- !>- O t- C3 C— y—t CO CJ3 +1 +i +1 +1 +1 +1 m m 谢 ο (0 砦 * * . * - ο m os cn 寸o 0¾ CO ΙΛ Cn3 CD CO 馬 CD CM c- ^ If?— CD CD CO r-t CO CO C*— r"H CD O C— t-H ifD CS3 €〇 t-H CQ Οά CJ> Χχλ +1 +1 +1 +1 +1 +i CO CU CxJ 艇 艇 t— 〇 c〇 C3 in> * CO 却 · • CQ 拿 CD <=> · • ΙΓ5 * T—( CO · •守 c— ΙΛ · • CO m ^+1 —+1 Ξ+Ι Ξ+Ι S+l =+1 c ta IT3 m m to lO _ I-H e i 1 Μ b ΰ〇 B r-H b〇 @ <=5 f-H i~H曰 f—H -5*3 m CO 键J ▼Ή 键C3 如 · e cd tl〇 · e <=> GO CO Jti · ^.CD b〇 — ^ · Ό €-* 陛X S=x LT5 X to X tlO ex ao ε x 叙-"1 C*J r*H CJ CO CD r—^ °co -41- (請先閲請背而之注意事項再蜞寫本頁). 裝. 訂 線. ΜΛ張尺度边用中SB家楳準（CHS)T4規格（210x297公龙) 經濟部屮央標準局A工消费合作杜印製 ' A 6 Π 6 五、發明説明（4Q) 表13 TTP以口服投藥12週後對以SRBC免疫之老鼠之免疫反應之影饗 週 第4 天後 第10 天後 PFC/106血液凝集素 PFC/10 6血液凝集素 %1~ -.[〇g2價數 %E- -l〇g2價數 數 脾細胞 脾細胞 薔薇體 19S+7S 7S 薔薇體 19S+7S 7S 3 15.2 565 6_,0 1.6 14.7 256 8.7 7.9 ±3.8 ±56 ±0..9 ±1.3 ±3.4 ±67 ±1.0 ±1.0 23.7* 1035* 7.5* 2.9* 23.5* 406* 10.4* 9.7* ±7.8 ±177 士 0..5 ±0.2 ±3·7 ±88 ±1·2 ±1.(Κ 5 13.8 422 5.,1 0 12.7 209 7.1 6.7 ±2.4 ±63 ±0.9 0 ±2·1 ±41 ±1.4 ±1.6 23.0* 933* 7.6* 2.7* 20.5* 430* 11.0Μ 11.0* ±6.1 ±248 ±1.5 ±1.5 ±2.7 ±86 ±1.2 ±1.0 7 12.8 495 4.6 0.5 14.0 245 8.8 7.9 ±2.9 ±85 ±1.1 ±0.9 ±5.1 ±48 ±1.6 ±1.6 20.5* 1120* 7.9* 2.Γ 26.9* 437* 11.3* 10.3* ±5.3 ±214 ±0.6 ±1.5 ±7.7 ±117 ±1.0 ±0.4 9 15.0 531 6.2 0.5 14.1 294 8.7 8.4 ±2.1 ±67 ±0.8 ±0.9 ±2.8 ±58 ±1.5 ± 1·5 18.6 1049* 7.7* 1.9 18.2* 515* 11.9* 10.5* ±2.8 ±184 ±0.7 ±1.2 ±3.4 ±530 ±0.8 ±1.0 12 15.0 573 7.2 1.4 16.5 266 7.5 7.1 ±2.6 ±143 ±1.0 ±1·2 ±2.6 ±58 ±1.1 ±0.8 14.1 770* 7.2 1.7 19.0 294 11.8* 10.6* ±2.7 ±132 ±1·4 ±1.7 ±4.1 ±65 ±0.4 ±1.0 *與對照组比較，在P=fl.05之统計學重要變數，各組中為40隻動物 -42- (請先閲讀背而之注意事項再填窍本頁) 裝- 訂 線. 本紙张尺度逡用中a »家楳毕（CNS)肀4規格(210x297公釐) 五、發明説明（4工） 經濟部屮央標準局员工消费合作社印製 II酿-Nilffidllis#:埋牿 fe · ：?薙-R铟·Ν®礤濉-3 链狯-E二槲 豳挺濉丨3 K- * 并 m co in t^- χλ • · · · 刺 +1 +1 +1 +1 CO O CO 05 • · · * i? οα co CT3 ς〇 y-H ΨΜ CO cn οο 侧 Csl CO csj CS3 •N +1 +1 +1 +1 ΟΟ I CO 〇〇 匪 CS3 ΙΛ ΙΟ CD r—Η r«H Η 〇 CO C3 ^―» ΙΛ ova co ·*τ + +1 +1 +1 +1 CO '-Η 0〇 CD 萌 CM CO CD GO ▼Ή i—* r—f t—{ tiffi袈键 *z^+lrs *〇〇·0+!0 ·00! 1二+|00.91 r Ζ+Ι9.Π a OO GO 00 GO m m 對照組 0 . lmg/kg 1 mg/kg 10 mg/kg -43- 本紙張尺度逍用中S a家樣毕(CNS)〒4規格(210x297公放） (請先閲讀背而之注意事項#填寫本頁) 裝· 線- 五、發明説明（42) A 6 Η 6 經濟部屮央榡準局β工消1\·-合作杜印製 敦酿-Ν劫®dll蕲辻埋性fe ••Ns親菪馬豳耜S1S6I刼《-fflglw 0 〇 1 1 t \ ζ-3 ίΧΜ CL·, 兹 πς m C<3 κ- m 細 m 铿 抝 * 关兴 00 〇 f—1 CS3 r-« CO CQ 1 CsJ ffO »—< +1+1+1+1 eg CO c〇 —CD 兮呀 ITD CD C3 CO r-H t-H κ- m 糊 •N m 坊 关 * 0〇 ΙΛ CO CD C>0 CO CO CD H t-H r~H +1 +1 +1 +1 OO CO CD r-H i—H C〇 €〇 ΙΟ !>- c— OO Ο + 姻 SI * * co co ^ CS3 CS3 T—» >r-H CO CQ Cs3 +1 +1 +1 +1 却 CD CD O 1-( CO Cvl trio CD CD CD < t—t T—t - m m 装 * 关 cn lo esa CO 呀 LO CO ^-H r-< CN3 +i +1 +1 +1 t—t c·*- ·<?* to 卜寸 C3 t--LO t~- CS] CD t-H c OO CO 0〇 CO _ m b£l DO txo jai jai end tie Q〇 be 陛，曰曰 兮 .—CD 她ο —1 舔撕蝌__4|琚仞『0=^梠•鼇丑绽匪辄^ * ........................^.....玎· · · 4 (請先叫請背而之注意事項洱填寫本頁) 本紙5艮尺度边《1中a Η家楳準（CNS) Ή規格(210X297公釐) 五、發明説明（43) Λ 6 Π 6 經濟部屮央標準局CX工消赀合作社印製 雞酿^劫迆0-.11|§辻逛性&，？：1||运詮|1运=+ 86139^-运雞酿《 91擗 貯存2個月後 在暗處室溫下 第4天 第10天 ς〇ι—tCOCNJ»—ICOCOCO CDCsICNJC^COt-HC^t-H +1^+1^+1^ +ι 关 兴 CD»-HlOt^-lf3C〇CDlO ITS « CD CS CD r-H C〇 O +i +t +i +i 在照光之室溫下 L____________________________________________ 第4天 第10天 5.0 9.5 ±1.1 ±2.1 5.4 10.8 ±0.8 ±0.7* 6.2 13.2 ± 0.3* ± 0.4* 4.8 10.6 ±1.3 ±2.4* 溫度+4 °C 第4天 第10天 关 * * L〇r-Hl〇C— C〇^-4CDCO — COCN3CS3CS3 +1^+1^+1^ +1 关 * C3 — OOCD£>-兮 COCO itd ·*—( tr- « co o co. o +1 +1 +1 +1 i it 4 y π π 1 第4天 第10天 * * 关 OOCO^COCNJi—tC3^ 05 C3 »—· CM T-H y-H T-H +1^+1^+1^ +i * * coo^^^oOco'^r'CNa lOCDt-OCOtOCOr—1 +1 +1 +1 +1 C Η< 〇〇 co co co _ m - it照組 0 . lmg/kg 1 rag/kg 10 mg/kg 1 (請先IVJ讀背而之注意事項#填寫本頁) 本紙张尺度逍用中a S家楳毕（CNS)肀4規格（210x297公釐） ^〇6Χνύ<ι) A 6 Π 6 五、發明説明（44) 經濟部+央標準局KX工消费合作社印製 K 壤 csa H- m 侧 蜮 铿 ίΚ ο τ·~Η >〇η W\ Η< 寸 戰 * 关 * i-H'^co^t'CDacoo^ CO ^ ^-H H t-H CD +1^+1^+1^ +1 cotr—t*-o^t— OiC'-cra OCOC3CI5CDOO +1 +1 +i +1 K- m 侧 m 坩 Η< CD 1—Η iftf> TO H< μ· 掀 * * * ^H^c=5cocot-tr-c=> O〇i-HC3C3C3CDOCN3 +1^+1^+1^ +1 eoo-oocjic—a^cOt— 〇C3CDaCZJC3CDC3 +1 +1 +1 +1 p 呀 m m H< 〇 >〇n H< 呀 til! 掀 * * * »-H^roO〇5ir3coo〇C5 〇〇 »—< CD T~H 1—H 05 +1 +1 Θ +1 +1 CO O- t— CT5 CO c— CO t— CDC3 0◦00 0.0 +1 +1 +1 +i i +j η ϊ 3 H< 〇 ifiP i〇\ 掀 关关关 CN3D— OOOCO^CSJCO CnCDCDT-HOOO^-l +1^+1^+1^ +1 co co cn CD O CD CD O CD +! +1 C OOOOOOOO _ m - too Wl uo ^xi 键 ti〇 tio oc 陛 5 曰 s 葙-“ —Ξ ........................夢· · ·β. · . .&(請先閲讀背而之注意事項洱塥寫本頁) 本紙ft尺度遑用中SH家標準（CNS)1?4規格(210X297公放） u Λ 6 Ιϊ 6 五、發明説明（45) 表18以lmg/天之劑量對健康志願者投與ΤΤΡ前與投與2週後之血液參數 經濟部屮央榀準历cx工消奸合作社印製 參數 安慰劑n=5 TTP n=5 0 14天 0 14天 红血球 X 10 6/^1 4.44±0.46 4.32±0.45 4.32±0.32 4.18±0.32 血紅素g/dl 12.4 ±2.5 11.9 ±2.8 12.8 ±0.8 11.8 ±0.6 血球容積％ 38.1 ±6.7 38 ±6.9 38.7 ±2.1 38.1 ±1.6 白血球 X 103 />ul 5.25±0.59 5.27±0.8 5.23±0.6 4.86±0.6 噻中性白血 球％ 52.6 ±12 57.6 ±11 54.2 ±2.5 55 ±3.6 淋巴细胞％ 26 ±7.5 30.4 ±8.3 34 ±4.1 32.4 ±5.3 血擔 X 103 /yul 220 ±40.4 214 ±35.8 221 ±38 214 ±39.6 血液沉降 mm/lh 7.6 ±9 5.6 ±1.9 7.8 ±2.7 6.8 ± 3.1 -47- 本紙5艮尺度逡用中as家槔毕（CNS)T4規格(2K1X297公釐） (請先閲讀背而之注意事項#填寫本頁) 裝- 線·* CM CN3 to H < H < ψ—i CSJ tH * -H • c- +1 +1 +1 +1 +1 b〇〇i〇P • CO CO • io in • CO cn o ml " a * Take * s eo CO QO CS3 CS3 ao Ε- »H < inch a +1 C5 +1 o +1 ί-H +1« -Η +1 3ΓΚ CO a S CQ CN3 tH ΙΛ tao o 5 * CO 兮 «s Take CO 〇o 〇o ira H < H < +1 CS3 +1 o +1 〇 + 1 +1 bo CD jjei one Zhu m C3 C < J oc = > CD 〇o LO g1 " am * take O m σΐ 〇〇OO CS3 s kan IK o ο f—4 »—H dare inch +1 +1 +1 +1 +! i < lC TO § ο s T— < 00 CO ΙΓ3 CD CO g 卜 · 兮 CNJ * »4 C = > rH CD rH» -H Bu · +1 +1 +1 +1 +1 Bloom m C ^ l Bu s CO in CO CO m CO 00 c— m H < tH o * — < C3 inch +1 +1 +1 +1 +1 city to CO CS3 00 tfi o < 〇CO s CO § 1 &, ms court suspect CO lO l > 03 CNJ —38- This paper standard Alpha is used in BID home Standard (CNS) T4 specification (210X297; it) (Please read the precautions first to write this page) Install-.is ^ Line-Λ 6 Π 6 V. Description of the invention (37) The Ministry of Economic Affairs and the Ministry of Economy, Industry and Consumer Affairs, Co., Ltd. made a joint print of ΠΡ 50 Bg / kg. Day η = 10 Hemagglutinin, ascended to -l〇g2 Day 4 Day 7 3.80 ± 0.87 " 4.90 ± 0.74 " 2.30 ± 1.41 5.33 ± 0.74 " 0.55 ± 0.83 2.55 ± 0.68 ** 0.00 4.33 ± 1.24 1.55 ± 1.49 4.30 ± 1.26 ΠΡ 10 mg / kg.day, η = 10 Day 4 Day 7 3.20 ± 0.87 ** 5.90 ± 1.70β 2.20 ± 0.97 5.70 ± 1.1 (Γ 0.60 ± 0.80 2.50 ± 1.1Γ 0.30 ± 0.64 3.25 ± 0.96 1.11 ± 0.99 4.40 ± 1.35 m Day 4 Day 7 1.75 ± 0.60 6.37 ± 1) .85 2.50 ± 0.70 6.12 ± 1.16 1.00 ± 0.89 3.80 ± 1.09 0.40 ± 0.48 3.66 soil \ 24 0.80 ± 0.97 3.80 ± 0.76 TTP — the number of administrations in a week CO 1〇 卜 03 04 -li ^ (please read the precautions before filling this page) · Order · Line. This paper uses 5T scales and uses 9 National Samples (CNS) < P4 specifications (210x297 g; ¢) Λ 6 Η 6 V. Invention description (38) Table 11 Immune effect of TTP (Soil SI)) TTP dose mg / kg η n PFC / 106 splenocytes on day 4% E-rose body day 4 hemagglutinin # 19S + 7S type 4 day hemagglutinin " Type 7S day 7 control group 30 469 13.6 5.4 8.2 ± 111 ± 3.2 ± 1. 1 ± 1.8 XX 0.5 10 997 15.6 6.8 8.4 ± 139 ± 1.4 ± 1.0 ± 1.1 XXXX 2.5 10 839 20.3 6.9 9.7 ± 177 ± 4.1 ± 1 · 0 ± 1.4 XXXX 5.0 10 746 23.2 7.2 9.8 ± 129 ± 4.7 ± 0.6 ± 1.4 XXXX 10.0 10 795 18.4 8.3 10.4 ± 129 ± 4.0 ± 1 · 8 ± 1.1 XX 25.0 10 560 16.3 & · 1 9.3 ± 145 ± 2.5 ± 1.1 ± 1.1 50.0 10 400 14.7 5.3 6.7 ± 57 ± 4.0 ± 1.0 ± 1.9 XXX 100.0 10 375 11.3 5.1 5.7 ± 67 ± 2.2 ± 0.8 ± 1.6 XXX 250.0 10 305 9.5 4.8 5.3 ± 67 ± 2.0 ± 1.1 ± 1.7 (please read the precautions on this page first) and install the line. The Ministry of Economic Affairs, Central Bureau of Examination, Ex-Work Consumer Television, and Du Yin 31 X statistically significant variables under the total comparison Q.Q5 (student t-test) * Shengzhi-l〇g2 " -40- This paper is used for standard China's 81 standard (CNS) T4 specifications (210x297): Λ 6 Π 6 V. Description of the invention (39) Central Bureau of Economic Development of the Ministry of Economic Affairs: Industrial-Consumer Cooperation Du Du «« dli-Nu ^ εΗ < φZΙ Η < Μ bC co CO 〇0 * CO CM CD C3 * inch 〇C〇LO 〇Ο — CO o〇tH 〇〇t ~ H CT3 tH 0 5 CN3 ώ j t-η o〇 »—« mmm mil / chat +1 +1 +1 +1 +1 +1 aluminum &! CO * * ο 00 c〇〇 卜 CD mo 啊 CO CJ5 OO CQ αά intercept + CT3 tH 03 τ—IO tH 03 · * —i O y— > 0〇tH CO zn cn »-H +1 +1 — + 1 +1 — + 1 +1 &N; ΰιΟ CO C5 CO 03 H lO CO 00 CD c ^ l C < J Ο r_H CO ◦ CD HO C3 O tH • N +1 +1 +1 +1 +1 +1 +1 mm CO BU CO r * H * — * i-Η O〇crs t > * Cold CO Cut H < Miscellaneous + LO tH C〇r—1 D-! ≫-O t- C3 C— y—t CO CJ3 +1 + i +1 +1 +1 +1 mm Xie ο (0 Zhai * *. *-Ο m os cn inch o 0¾ CO ΙΛ Cn3 CD CO Ma CD CM c- ^ If? — CD CD CO rt CO CO C * — r " H CD OC— tH ifD CS3 € 〇tH CQ Οά CJ > Χχλ +1 +1 +1 +1 +1 +1 + i CO CU CxJ boat t— 〇c〇C3 in > * CO but · CQ takes CD < = > · ΙΓ5 * T— (CO · • Shou c— ΙΛ • • CO m ^ + 1 — + 1 Ξ + Ι Ξ + Ι S + l = +1 c ta IT3 mm to lO _ IH ei 1 Μ b ΰ〇B rH b〇 @ < = 5 fH i ~ H said f—H -5 * 3 m CO key J ▼ Ή key C3 eg · e cd tl〇 · e < = > GO CO Jti · ^ .CD b〇— ^ · Ό €-* 陛 XS = x LT5 X to X tlO ex ao ε x scription- " 1 C * J r * H CJ CO CD r— ^ ° co -41- (please read the notes before you write this page). Pack. Thread. ΜΛ 张Standards for the use of SB family 戳 擳 (CHS) T4 specifications (210x297 gongs) A printed by the industrial and consumer cooperation of the Central Standards Bureau of the Ministry of Economic Affairs A 6 Π 6 V. Description of the invention (4Q) Table 13 TTP administered orally 12 After weeks, the immune response to SRBC-immunized mice will be affected by PFC / 106 hemagglutinin PFC / 10 6 hemagglutinin% 1 ~-. [〇g2valent% E-- l〇g2 valence number splenocytes splenocytes rosette 19S + 7S 7S rosette 19S + 7S 7S 3 15.2 565 6_, 0 1.6 14.7 256 8.7 7.9 ± 3.8 ± 56 ± 0..9 ± 1.3 ± 3.4 ± 67 ± 1.0 ± 1.0 23.7 * 1035 * 7.5 * 2.9 * 23.5 * 406 * 10.4 * 9.7 * ± 7.8 ± 177 ± 0..5 ± 0.2 ± 3 · 7 ± 88 ± 1 · 2 ± 1. (Κ 5 13.8 422 5., 1 0 12.7 209 7.1 6.7 ± 2.4 ± 63 ± 0.9 0 ± 2 · 1 ± 41 ± 1.4 ± 1.6 23.0 * 933 * 7.6 * 2.7 * 2 0.5 * 430 * 11.0Μ 11.0 * ± 6.1 ± 248 ± 1.5 ± 1.5 ± 2.7 ± 86 ± 1.2 ± 1.0 7 12.8 495 4.6 0.5 14.0 245 8.8 7.9 ± 2.9 ± 85 ± 1.1 ± 0.9 ± 5.1 ± 48 ± 1.6 ± 1.6 20.5 * 1120 * 7.9 * 2.Γ 26.9 * 437 * 11.3 * 10.3 * ± 5.3 ± 214 ± 0.6 ± 1.5 ± 7.7 ± 117 ± 1.0 ± 0.4 9 15.0 531 6.2 0.5 14.1 294 8.7 8.4 ± 2.1 ± 67 ± 0.8 ± 0.9 ± 2.8 ± 58 ± 1.5 ± 1.55 18.6 1049 * 7.7 * 1.9 18.2 * 515 * 11.9 * 10.5 * ± 2.8 ± 184 ± 0.7 ± 1.2 ± 3.4 ± 530 ± 0.8 ± 1.0 12 15.0 573 7.2 1.4 16.5 266 7.5 7.1 ± 2.6 ± 143 ± 1.0 ± 1.2 ± 2.6 ± 58 ± 1.1 ± 0.8 14.1 770 * 7.2 1.7 19.0 294 11.8 * 10.6 * ± 2.7 ± 132 ± 1.4 ± 1.7 ± 4.1 ± 65 ± 0.4 ± 1.0 * Compared with the control group , The statistically significant variable at P = fl.05, 40 animals in each group-42- (please read the precautions before filling in this page) Binding-Stroke. This paper size is used in a »Carbon Bi (CNS) 4 specifications (210x297 mm) V. Description of the invention (4 workers) Printed II brew-Nilffidllis #: 讙 牿 fe ·:? 薙 -R indium · Ν® 礤 濉 -3 狯 狯 -E 二 quercean濉 丨 3 K- * and m co in t ^-χλ • thorn +1 +1 +1 +1 CO O CO 05 • · * i? Οα co CT3 ς〇yH ΨΜ CO cn οο side Csl CO csj CS3 • N +1 +1 +1 +1 ΟΟ I CO 〇〇 bandits CS3 ΙΛ ΙΟ CD r—Η r «H Η 〇CO C3 ^ ―» ΙΛ ova co * τ + +1 +1 +1 +1 CO '-Η 0〇CD 萌 CM CO CD GO ▼ Ή i— * r—ft— {tiffi loop key * z ^ + lrs * 〇〇 · 0 +! 0 · 00! 1 二 + | 00.91 r ζ + Ι9 .Π a OO GO 00 GO mm Control group 0. Lmg / kg 1 mg / kg 10 mg / kg -43- This paper standard is used in the Sa family sample (CNS) 〒 4 specifications (210x297 public release) (please First read the back and the matters needing attention # fill out this page) 装 · 线-V. Description of invention (42) A 6 Η 6 Ministry of Economic Affairs 屮 楊 榡 斡 局 β 工 消 1 \ · -Cooperative Duyin-Dun Brewing-Νaboo ®dll burrowing fe •• Ns pro-scrambled horse S1S6I 刼 《-fflglw 0 〇1 1 t \ ζ-3 ίΧΜ CL ·, ππς m C < 3 κ- m fine m 铿 拗 * Guanxing00 〇f—1 CS3 r- «CO CQ 1 CsJ ffO» — < + 1 + 1 + 1 + 1 eg CO c〇—CD 呀呀 ITD CD C3 CO rH tH κ- m paste • N m Fangguan * 0 〇ΙΛ CO CD C > 0 CO CO CD H tH r ~ H +1 +1 +1 +1 OO CO CD rH i—HC〇 € 〇ΙΟ! ≫-c— OO Ο + marriage SI * * co co ^ CS3 CS3 T— »> rH CO CQ Cs3 +1 +1 +1 +1 but CD CD O 1- (CO Cvl trio CD CD CD < t—t T—t-mm Pack * Off cn lo esa CO ye LO CO ^ -H r- < CN3 + i +1 +1 +1 t—tc · *-· <? * To Bu Cun C3 t--LO t ~-CS] CD tH c OO CO 0〇CO _ mb £ l DO txo jai jai end tie Q〇be 陛, say something. —CD her ο —1 licking tears __4 | 琚 伞 『0 = ^ 梠 • Ao ugly ugly bandits ^ * ............. ........... ^ ..... 玎 ··· 4 (please call the back-up precautions and fill in this page) 5 pages of this paper, "1 in a Η 家 楳 quasi (CNS) Ή specification (210X297mm) V. Description of the invention (43) Λ 6 Π 6 CX Gongxiao Zheng Cooperative of the Ministry of Economic Affairs, CX Gongxiaozheng Cooperative Printed Chicken Stuffed ^ robber 0-.11 | § 辻 費 性 & ,? ： 1 || 运 詢 | 1 运 = + 86139 ^ -Yun chicken stuffing "91 擗 Stored for 2 months and stored in the dark at room temperature on the fourth day and the tenth day ς〇ι—tCOCNJ» —ICOCOCO CDCsICNJC ^ COt-HC ^ tH + 1 ^ + 1 ^ + 1 ^ + ι Guanxing CD »-HlOt ^ -lf3C〇CDlO ITS« CD CS CD rH C〇O + i + t + i + i at the room temperature of the light L____________________________________________ 4th Day 10 Day 5.0 9.5 ± 1.1 ± 2.1 5.4 10.8 ± 0.8 ± 0.7 * 6.2 13.2 ± 0.3 * ± 0.4 * 4.8 10.6 ± 1.3 ± 2.4 * Temperature +4 ° C Closed on Day 4 and Day 10 * * L〇r- Hl〇C— C〇 ^ -4CDCO — COCN3CS3CS3 + 1 ^ + 1 ^ + 1 ^ +1 Off * C3 — OOCD £ > -Ci COCO itd · * — (tr- «co o co. O +1 +1 +1 +1 i it 4 y π π 1 Day 4 Day 10 * * Off OOCO ^ COCNJi—tC3 ^ 05 C3 »— · CM TH yH TH + 1 ^ + 1 ^ + 1 ^ + i * * coo ^ ^^ oOco '^ r'CNa lOCDt-OCOtOCOr—1 +1 +1 +1 +1 C Η < 〇〇co co co _ m-it according to the group 0. lmg / kg 1 rag / kg 10 mg / kg 1 ( Please read IVJ reading back first #Fill in this page) This paper standard is used in a small size (CNS) Yu 4 specifications (210x297 mm) ^ 〇6Χνύ &ι; A 6 Π 6 V. Description of invention (44) Ministry of Economy + Central Printed by the quasi-bureau KX industrial and consumer cooperatives K soil csa H- m side beetle ίκ ο τ · ~ Η > 〇η W \ Η < inch war * Off * i-H '^ co ^ t'CDacoo ^ CO ^ ^ -HH tH CD + 1 ^ + 1 ^ + 1 ^ +1 cotr—t * -o ^ t— OiC'-cra OCOC3CI5CDOO +1 +1 + i +1 K- m side m Cr Η < CD 1—Η iftf > TO H < μ · lift * * * ^ H ^ c = 5cocot-tr-c = > O〇i-HC3C3C3CDOCN3 + 1 ^ + 1 ^ + 1 ^ +1 eoo-oocjic—a ^ cOt— 〇C3CDaCZJC3CDC3 + 1 +1 +1 +1 p ah mm H < 〇 > 〇n H < til! Lift * * * »-H ^ roO〇5ir3coo〇C5 〇〇» — < CD T ~ H 1—H 05 + 1 +1 Θ +1 +1 CO O- t— CT5 CO c— CO t— CDC3 0◦00 0.0 +1 +1 +1 + ii + j η ϊ 3 H < 〇ifiP i〇 \ 关 关 关 关 CN3D — OOOCO ^ CSJCO CnCDCDT-HOOO ^ -l + 1 ^ + 1 ^ + 1 ^ +1 co co cn CD O CD CD O CD +! +1 C OOOOOOOO _ m-too Wl uo ^ xi key ti〇tio oc 陛5 said s 葙-"—Ξ ........................ dream · · · β. · &Amp; (please read the opposite first Matters needing attention Er Er wrote this page) The ft scale of this paper is used in the SH home standard (CNS) 1? 4 specifications (210X297 public release) u Λ 6 Ιϊ 6 V. Description of the invention (45) Table 18 with lmg / Day of the dose to healthy volunteers before and 2 weeks after the TTP administration blood parameters of the Ministry of Economic Affairs of the Central Committee of the Cx Gongxian rape cooperatives printed parameters placebo n = 5 TTP n = 5 0 14 days 0 14 Hemoglobin X 10 6 / ^ 1 4.44 ± 0.46 4.32 ± 0.45 4.32 ± 0.32 4.18 ± 0.32 Heme g / dl 12.4 ± 2.5 11.9 ± 2.8 12.8 ± 0.8 11.8 ± 0.6 Hematocrit% 38.1 ± 6.7 38 ± 6.9 38.7 ± 2.1 38.1 ± 1.6 leukocyte X 103 /> ul 5.25 ± 0.59 5.27 ± 0.8 5.23 ± 0.6 4.86 ± 0.6 neutrophil leukocyte% 52.6 ± 12 57.6 ± 11 54.2 ± 2.5 55 ± 3.6 lymphocyte% 26 ± 7.5 30.4 ± 8.3 34 ± 4.1 32.4 ± 5.3 Blood burden X 103 / yul 220 ± 40.4 214 ± 35.8 221 ± 38 214 ± 39.6 Blood sedimentation mm / lh 7.6 ± 9 5.6 ± 1.9 7.8 ± 2.7 6.8 ± 3.1 -47 Completion (CNS) T4 specification (2K1X297mm) (please read the notes on the back first #fill this page)

οru I ΰ Q 66 ΛΠ 五、發明説明（46) 經濟部屮央榀準局Α工消#合作社印製 表19以lmg/天劑量對健康志願者以TTP投藥前及投藥後2週之血液參數 參 數 安慰劑n=5 0 14天 ΤΤΡ η=5 〇 14天 總蛋白質g/1 72.8 ±1.76 68.42土3.2 73.8 ±1.92 70 ±5.5 蛋清％ 63.2 ±2.5 63.8 ±2·3 63.6 ±1.8 64.4±2.1 球蛋白α1 % 3.1 ±(Μ 3 ±0.5 2.8 ±0.5 2.8±0.45 球蛋白cr2 % 5.95土 1.9 6.8 ±1.5 6.93±0.9 〇6.9±0.9 球蛋白彡％ 14.4 ±2.2 14.2 ±1.5 13.3 ±1.9 13.2±1.3 球蛋白y % 12.2 ±1.5 12.1 ±1.3 13.7 ±0.9 12.3±1 IgG g/1 10.3 ±1.1 10.2 ±1 11.7 ±1.6 11.1±1.4 IgA g/1 1.8 ±0.6 1.9 ±0.5 1.8 ±0.5 1.9±0.5 IgM g/1 1.4 ±0.3 1.4 ±0.2 1.1 ±0.2 1.1±0.4 補體C3 g/1 1.1 ±0.1 1.1 ±0.1 1.1 ±0.2 0.2±0.2 補體C4 g/1 0.2 ±0.5 9.3 ±0.04 0.2 ±0.0 0.2±0.03 丙胺酸D/l 34.2 ±0.05 0.3 ±0.04 30.2 ±8.2 31.2±3.2 天冬胺酸U/l 32.8 ±4.4 40.2±6.6 30.4 ±7.1 39.6±6.6 (請先閲請背而之注意事項#塥寫本頁) 裝- 訂_ 線· 本紙张尺度边用中S S家標準(CNS〉T4規格(210x297公;it) 五、發明説明（47) Λ 6 Π 6 表20 對2組以ΤΤΡ處理及以安慰劑處理之病患在1990年10月期間， 及1989及1990年最後一季期間呼吸道急性傳染之頻率比較 ΤΤΡ 1990年第4季施用期間 η 1989年第4 1990年第4季 統計學 季（無ΤΤΡ) (以ΤΤΡ處理） 重要性 每位病人之 每位病人之 平均傳染數 平均傳染數 V’ 感 冒 20 4 .〇 ± 1.3 1.0± 0.5 < 0.01 喉 病 20 3·3± 1.3 0.8± 0.6 < 0.01 面疱疹 20 2 · 1 土 2.2 0.3± 0.4 < 0.01 咳 嗽 20 1.4土 1.1 0·3± 0·6 < 0.01 支氣管炎 20 0.3± 0.5 0 肺 炎 20 0.2± 0.9 0 安慰劑 在1990年第4季期間施用 η 1989年第4 1990年第4季 統計學 季（無ΤΤΡ) (以ΤΤΡ處理） 評估差異 每位病人之 每位病人之 平均傳染數 平均傳染數 "Ρ" 感 冒 20 3.9土 1.4 3.1± 1.5 > 0.05 喉 痛 20 2.3± 2.0 2.6± 1.7 > 0.05 面疱疹 20 2·3± 1.8 1.7± 2_1 > 0.05 咳 嗽 20 1,5 土 1.5 1.9± 2.0 > 0.05 支氣管炎 20 0.1± 0.3 0.1± 0.3 肺 炎 20 0.1± 0.3 0.1± 0.3 (請先閱讀背而之注意事項洱埙寫本頁) 裝- 線. 經濟部屮央榀準局cx工消伢合作杜印製 -49- 本紙尺度边用中a Η家標準（CNS)>r4規格（210x297公;«：) 五、發明説明（48) 經濟部屮央橾準局！Ξ：工消奸合作杜印31 ^酴^(躲瓛镞龄苺 碁«) VHdtiM^SMfrwll-Nsi^o-lE-lIKS^ttli-^Yiοru I ΰ Q 66 ΛΠ V. Description of the invention (46) The Ministry of Economic Affairs, Pyongyang quasi-bureau Α 工 消 # Cooperative printed table 19 Blood parameters before and after TTP administration to healthy volunteers at a dose of 1 mg / day with TTP Parameters Placebo n = 5 0 14 days TTP η = 5 〇14 days total protein g / 1 72.8 ± 1.76 68.42 ± 3.2 73.8 ± 1.92 70 ± 5.5 egg white% 63.2 ± 2.5 63.8 ± 2.3 63.6 ± 1.8 64.4 ± 2.1 balls Protein α1% 3.1 ± (Μ 3 ± 0.5 2.8 ± 0.5 2.8 ± 0.45 globulin cr2% 5.95 ± 1.9 6.8 ± 1.5 6.93 ± 0.9 〇6.9 ± 0.9 globulin ≦% 14.4 ± 2.2 14.2 ± 1.5 13.3 ± 1.9 13.2 ± 1.3 globule Protein y% 12.2 ± 1.5 12.1 ± 1.3 13.7 ± 0.9 12.3 ± 1 IgG g / 1 10.3 ± 1.1 10.2 ± 1 11.7 ± 1.6 11.1 ± 1.4 IgA g / 1 1.8 ± 0.6 1.9 ± 0.5 1.8 ± 0.5 1.9 ± 0.5 IgM g / 1 1.4 ± 0.3 1.4 ± 0.2 1.1 ± 0.2 1.1 ± 0.4 Complement C3 g / 1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.2 0.2 ± 0.2 Complement C4 g / 1 0.2 ± 0.5 9.3 ± 0.04 0.2 ± 0.0 0.2 ± 0.03 Alanine D / l 34.2 ± 0.05 0.3 ± 0.04 30.2 ± 8.2 31.2 ± 3.2 aspartic acid U / l 32.8 ± 4.4 40.2 ± 6.6 30.4 ± 7.1 39.6 ± 6.6 (please read the notes on the back # 塥 write this page) -Order _ Line · The SS standard (CNS> T4 specification (210x297 g; it)) for this paper ’s standard. V. Description of the invention (47) Λ 6 Π 6 Table 20 For 2 groups treated with TTP and placebo Comparison of the frequency of acute respiratory infections in patients during October 1990 and the last quarter of 1989 and 1990 TTP Application period of the fourth quarter of 1990 η The fourth quarter of 1989 The statistical quarter of the fourth quarter of 1990 (no TTP) (with TTP treatment) Importance Average number of infections per patient Average number of infections V 'Cold 20 4 .0 ± 1.3 1.0 ± 0.5 < 0.01 Throat disease 20 3.3 ± 1.3 0.8 ± 0.6 < 0.01 Facial herpes 20 2 · 1 soil 2.2 0.3 ± 0.4 < 0.01 cough 20 1.4 soil 1.1 0 · 3 ± 0 · 6 < 0.01 bronchitis 20 0.3 ± 0.5 0 pneumonia 20 0.2 ± 0.9 0 placebo administered during the fourth quarter of 1990 η The fourth quarter of 1989 The statistical quarter of the fourth quarter of 1990 (without TTP) (treated with TTP) The difference between the average number of infections per patient and the average number of infections per patient " Ρ " cold 20 3.9 soil 1.4 3.1 ± 1.5 > 0.05 Sore throat 20 2.3 2.0 2.6 ± 1.7 > 0.05 Facial herpes 20 2 · 3 ± 1.8 1.7 ± 2_1 > 0.05 Cough 20 1,5 soil 1.5 1.9 ± 2.0 > 0.05 Bronchitis 20 0.1 ± 0.3 0.1 ± 0.3 Pneumonia 20 0.1 ± 0.3 0.1 ± 0.3 (please read the precautions for Erxun to write this page first) Installation-line. The CX Industry and Consumer Affairs Bureau of the Ministry of Economic Affairs cx industrial and consumer cooperation in cooperation with the du printing -49- This paper standard is used in a Η home standard (CNS) > r4 specification (210x297 g; «:) V. Description of invention (48) Ministry of Economic Affairs, Central Bureau of Preservation! Ξ ： Work to eliminate rape cooperation Du Yin 31 ^ 酴 ^ (Hou Rong Ling Bing 碁 «) VHdtiM ^ SMfrwll-Nsi ^ o-lE-lIKS ^ ttli- ^ Yi

NaCl 0.9% CO \ 1 l i \ 1 ¢-4 ft 1 1 1 1 1 1 1 1 ta CO t 1 1 1 ① u Cu 1 1 1 讓 CQ +1 1 +i \ + + + + CD U CL, 1 +1 +1 +1 十 +1 Λ球A eo +1 + + + + 1 1 + + 十 ① 〇4 +i + + + 1 1 1 + + + 結核菌素 RTaa CQ + + + + 1 +1 + + + + + CU SU 〇4 + 1 + 4· 1 1 + + 1 + + mm 5 E-H CQ Cx2 O-i SCJ SC. as > as 3： z K3 ac CO Csl CO io to c〇 —50— 本紙5t尺度边用中9國家標毕（CNS)<P4規格（210X297公;!t) (請先閲請背而之注意事項洱堝寫本頁) 裝· 線- s eeoaad 五、發明説明（49) A 6 η 6 經濟部屮央標準局β工消费合作社印製 SI礆-Ns+tle^vHd锘蚝拓涸堤旮(匿菡俶)舶、遐》镟伥迄CN3Z槲 .~~(次 KJ3 C73 ed · SZ 〇 CO 1 l 1 1 α> 口 α 1 ( 1 < Μ Q-ι CQ 1 1 \ CD t-i 〇4 1 1 i m 掘撇 細:\ CQ t +! I + + + + Φ 〇4 +1 +1 +1 1 +1 + 溷贼 S按 嫌 CD CQ + + 1 + 十 +1 + - + ·+· +·. ① (-* 〇4 + 1 + + f + + + + + 蘇 坻S m CQ 1 + + 十 + 1 1 + «+· 1 1 O) U( Cu 1 + + + 1 1 + + 1 1 .sc ac t-H CD o »~3 3= C_5 >~3 3C 3c 03 CNJ CO LO CO 卜 〇o -51- 本紙張尺度逍用中SB家標毕（CNS)T4規格(210x297公;!t) (請先閱讀背而之注意事項典蜞寫本頁) 裝- *γφ ' 線· 逛國εCo 铝铟餿ajd B 6 五、發明説明（5〇) 經濟部屮央標準局A工消伢合作杜印製 _免讓a mg%_ m WM 1 w 褪 1732·87± 207.52 283.87± 44.10 189.75 ± 75.15 1972.00± 239.33 285.50± 56.76 232.87± 65.45 ZD hC ►—« IgA ac tl〇 h-H ZD tU3 h-H < tio (-H SC 如 μ—< c— CO cn CD Cvl mil TO 蠛 1 732.87± 207.52 · 304.25 ± 47.50 202.87± 71.12 1 924.37 ± 246.25 296.50 ± 59.84 242 . 1 2 ± 56.95 CD HO l-H -< tk〇 μ-t ac be t—* CD ti〇 H-H -< ϋύ *—» ac tafi 1—~1 τΉ c^a CQ ^r ΙΓ3 CO 測試組 < I： PQ 0 0 00 ιο ιο ιλ C3 C3 C? CD Ο CD 八八八 α>4 〇_< CD 1-Η <ΝΙ ι—Ι t—Η t-H WWW > > > ΙΛ ΙΟ ΙΓ3 C3 O ◦ CD CD CD 八八 A Cii 〇4 cu 卜 oo cn cn cn (〇 > > > -52- 本紙5fc尺度逍用中國B家楳毕（CHS)肀4規格(210X297公址） LO ΙΟ ΙΛ ◦ C3 ◦ • « · C3 CD α 八A A CU Put O-i 〇 1—t CV3 W CO w > > > t- CO CJ3 lO LO ΙΛ CD C3 ◦ CD CD ◦ 八八八 〇4 Cu cm cn cn cn > > > 跡+i据 (請先閲諳背而之注意事項洱填寫本頁) 裝· 訂_ 線·NaCl 0.9% CO \ 1 li \ 1 ¢ -4 ft 1 1 1 1 1 1 1 1 1 ta CO t 1 1 1 ① u Cu 1 1 1 Let CQ +1 1 + i \ + + + + CD U CL, 1 +1 +1 +1 ten +1 Λ ball A eo +1 + + + + 1 1 + + ten ① 〇4 + i + + + 1 1 1 + + + tuberculin RTaa CQ + + + + 1 +1 + + + + + CU SU 〇4 + 1 + 4 · 1 1 + + 1 + + mm 5 EH CQ Cx2 Oi SCJ SC. As > as 3: z K3 ac CO Csl CO io to c〇—50— original paper The 5t scale is used in the National 9 National Standard (CNS) < P4 specification (210X297;! T) (please read the notes on the back to write this page on the back) Erection · line-s eeoaad V. Description of invention ( 49) A 6 η 6 Siong-Ns + tle ^ vHd printed by the β-Consumer Cooperative Society of the Central Standards Bureau of the Ministry of Economic Affairs. Secondary KJ3 C73 ed · SZ 〇CO 1 l 1 1 α > port α 1 (1 < Μ Q-ι CQ 1 1 \ CD ti 〇4 1 1 im excavation skimming: \ CQ t +! I + + + + Φ 〇4 +1 +1 +1 1 +1 + thief S according to CD CQ + + 1 + ten + 1 +-+ + + +. ① (-* 〇4 + 1 + + f + + + + + Sudi S m CQ 1 + + ten + 1 1 + «+ · 1 1 O) U (Cu 1 + + + 1 1 + + 1 1 .sc ac tH CD o »~ 3 3 = C_5 > ~ 3 3C 3c 03 CNJ CO LO CO 卜 〇o -51- This paper size is easy to use China SB home standard (CNS) T4 specification (210x297 g;! T) (please read the precautions first to write this page) Pack-* γφ 'line · visit the country εCo aluminum indium glutinous adjd B 6 5. Description of the invention (5〇) Cooperated with the Consumer Industry Standards Bureau of the Ministry of Economic Affairs to print and print _ free of a mg% _ m WM 1 w fade 1732 · 87 ± 207.52 283.87 ± 44.10 189.75 ± 75.15 1972.00 ± 239.33 285.50 ± 56.76 232.87 ± 65.45 ZD hC ►— «IgA ac tl〇hH ZD tU3 hH < tio (-H SC such as μ-< c-- CO cn CD Cvl mil TO 蠛 1 732.87 ± 207.52 246.25 296.50 ± 59.84 242. 1 2 ± 56.95 CD HO lH-< tk〇μ-t ac be t— * CD ti〇HH-< ϋύ * — »ac tafi 1— ~ 1 τΉ c ^ a CQ ^ r ΙΓ3 CO test group < I: PQ 0 0 00 ιο ιο ιλ C3 C3 C? CD Ο CD 八八 八 α > 4 〇_ < CD 1-Η < ΝΙ ι—Ι t—Η tH WWW > > > ΙΛ ΙΟ ΙΓ3 C3 O ◦ CD CD CD 八八 A Ci i 〇4 cu oo cn cn cn (〇 > > > -52- 5fc scale of the paper for the Chinese B family tree (CHS) Yu 4 specifications (210X297 public address) LO ΙΟ ΙΛ ◦ C3 ◦ • «· C3 CD α Eight AA CU Put Oi 〇1—t CV3 W CO w > > > t- CO CJ3 lO LO ΙΛ CD C3 ◦ CD CD ◦ 八八 八 〇4 Cu cm cn cn cn > > >; Trace + i data (please read the precautions and fill in this page first) Pack · Order _ Line ·

Claims (1)

A1 B" Cl D1 專利申請案第31 103003 f ROC Patent Appln. No. 81 103008 修正之申請專利範圍中文本-附件㈠ Amended Claims in C h ϊ π p s p - F!nr»l. (民國82年4月l〇日送呈） (Submitted on April 10, 1993) {琦先閱話背面之ΐ!意事項再填tf本百) 經 濟 邾 中 央 標 準 局 工 消 費 合 作 杜 製 1. 一種可裂備成固態之泥煤一衍生之生物括性產物之裂 備方法*其係由無機發頚（尤其是氯化鈉）之绖高度猥 缩之水溶疲裂’備，且該水溶液可藉下列方式製得：將 空氣乾燥之粗艰煤物質行一级或二级鹺性水解，接著 酸化此水解物，Μ有機溶劑萃取以分離不可溶部份及 除去底部物質，其特歡為以脫項質水稀釋該溶掖並令 其進行逆滲透作用Μ便將溶掖脫鹽而移除無機留類， 及其中將生成之溶疲濃缩與淨化，及選擇地滅菌 或噴蓊乾燥。 2. 如申請專'利範圍第1項之方法•其中該稀釋作用係Μ 相對於該溶掖證積之數倍（宜為5至8倍）膣積水進 行 -53 93-A\3\9torf.261-Υ k. -綠· 木s 5Uii；i(CNS)以规格（210^297公犮） •i<υ ΰ A B c D ¾ -Α+ IJ -ΡΊ- 六 經濟部中夬標準局員工消費合作杜印- 3 .如申請專利範圍第i項之方法，其中忽绖濃缩與淨化 之溶筱之滅菌係以薄膜過绽器除菌，例如， Mi 11 過濾器。 4. 如$請專利範圍第1至3項中任一項之方法，其中噴菝 乾缲係將該绖濃缩舆淨化之溶掖K入口溫度為约180 t； *且出口溫度约90*0進行。 5. 如串請專利範圍第丨至3項中任一項之方法，其中所製 得之產物為滠缩液形式。 . 6. 如申請專利範圍第1至3項中任一項之'方法，其中所裂 得之產物係用來裂備凝膠或軟資形式之路藥组成物。 種裂備含泥煤一衍生之生物活性產物之凝膠之方法 •其特戡為將滅菌之酒精第草萃取物與： ·?* (a) 粉末狀之泥煤一衍生之生物活性產物之除菌水溶 掖， (b) 還自包括薄荷醇、百里酚、薄荷、桴樺、及按樹 之詞味用化合物之除菌溶液* (c) 凝膠形成组成物，如除菌之甘油與膠體二氧化矽 以使掖證组成物變成凝膠形式，其中液體混合物對二 氧化矽之重量比宜為90: 10至94:6 。 (請先5?讀背νΒ之：！一一意事項再填寫本百 •ν'. •線· -54 * Km AT B7 CT DT .一種製備含泥煤一衍生之生物活性產激之軟資之方法 ，其持徵為将滅菌之藥草萃取物與粉末狀泥煤一衍生 之生物话性產物漸漸结合’所得之混合物每^加入*ΐ 膠形成成分（如膠證二氧化矽）凝膠化’且所得之凝 膠以含脂肪成份（如eucerine及凡士林）之绖事先域 菌混合物予Μ碾裂，其中液體成份對二氧化矽之重量 比宜為约30 : 20，且凝膠對脂肪组成物之比宜為32 : 68至 34 : _66 0 .如_請專利範圍第1、2、3、7或8項之方法，其持激 為泥煤一衍生之生物活性產物係” T0LPA<R>朵芙裂備 物”。 -.T先閱枝背面之注意事項再填寫本百) _,A_ 經濟部中夬標準局員工消费合作社印製 -綠· -55 不认泣尺度边·'。丨，S S 5：彷毕（〇fS)屮4规»(2丨〇父297公竑）A1 B " Cl D1 Patent Application No. 31 103003 f ROC Patent Appln. No. 81 103008 Amended Claims in Chinese-Annex ㈠ Amended Claims in C h ϊ π psp-F! Nr »l. Submitted on the 10th of the month) (Submitted on April 10, 1993) (Qi first read the words on the back of the page! Note and then fill in tf) Hundreds of Economy, Central Standards Bureau, Industry and Consumer Cooperation Control 1. A kind of cracked ready to be solid Peat-derived biological products including cracking method * It is prepared by the highly shrinking water-soluble fatigue of inorganic hairpins (especially sodium chloride), and the aqueous solution can be prepared by: The air-dried coarse refractory coal material is subjected to primary or secondary hydrolyzation, followed by acidification of the hydrolysate, Μ organic solvent extraction to separate the insoluble part and remove the bottom material, which is especially diluted with dehydrated water Tuck and allow it to perform reverse osmosis. M will desalt the solution and remove inorganic residues, and concentrate and purify the generated solution, and optionally sterilize or spray dry. 2. If applying for the method of the first item of the scope of “Professional Benefits” • where the dilution effect is carried out on the accumulated water of several times (preferably 5 to 8 times) with respect to the dissolution certificate -53 93-A \ 3 \ 9torf .261-Υ k. -Green · wood s 5Uii; i (CNS) with specifications (210 ^ 297 gong) • i < υ ΰ AB c D ¾ -Α + IJ -ΡΊ- Six employees of the Ministry of Economic Affairs, Central Standards Bureau Consumer Cooperation Du Yin-3. As the method of item i in the scope of patent application, in which the sterilization of the concentrated solution of purgation and purification is sterilized by a thin film filter, for example, Mi 11 filter. 4. The method as described in any one of items 1 to 3 of the patent application scope, in which the dry stalk of Smilax glabra is the temperature at which the inlet K of the concentrated and purified knot is about 180 t; * and the outlet temperature is about 90 * 0 proceed. 5. If the method of any one of items 丨 to 3 of the patent scope is applied for, the product obtained is in the form of shrinkage liquid. 6. The 'method as described in any one of items 1 to 3 of the patent application scope, in which the cracked product is used to crack the road drug composition in the form of a gel or soft capital. A method of preparing a gel containing a peat-derived biologically active product. The special method is to extract the sterilized alcohol and grass extract with: ·? * (A) Powdered peat-derived biologically active product Sterilizing water dissolving, (b) also from sterilizing solution including menthol, thymol, peppermint, almond, and tree-flavored compounds * (c) gel-forming composition, such as sterilized glycerin With colloidal silicon dioxide to make the composition into gel form, the weight ratio of liquid mixture to silicon dioxide is preferably 90:10 to 94: 6. (Please read the first 5? Read the νΒ :! One by one, and then fill in the hundred. Ν '. • Line. -54 * Km AT B7 CT DT. A soft resource for the preparation of a bioactive productive stimulus containing peat-derived The method is characterized by gradually combining the sterilized herbal extract with the powdered peat-derived biological product ', and adding the gel-forming ingredients (such as colloidal silica) to the resulting mixture for gelation 'And the resulting gel is grinded with a mixture of entwined bacteria containing fat ingredients (such as eucerine and petrolatum), and the weight ratio of liquid ingredient to silica is preferably about 30:20, and the gel to fat composition The material ratio should be 32: 68 to 34: _66 0. If the method of item 1, 2, 3, 7 or 8 of the patent application is requested, the stimulus is a bioactive product derived from peat-based “T0LPA < R >; Duo Fu crack preparation ". -.T Read the notes on the back of the branch first and then fill out the hundred) _, A_ Printed by the Employee Consumer Cooperative of the Zhongshang Standards Bureau of the Ministry of Economic Affairs-Green · -55 Do not recognize the standard side. '丨, S S 5: imitation (〇fS) 4 regulations »(2 丨 〇 father 297 Gong Hong)